Enhanced targeted genome modification using programmable DNA-binding proteins

By binding programmable DNA-binding proteins near target chromosome sequences, the accessibility and specificity of programmable DNA modification proteins such as CRISPR/Cas nucleases have been improved, solving the problems of poor accessibility and low specificity in targeted genome modification and enabling efficient genome and epigenetic modification in human cells.

CN116064529BActive Publication Date: 2026-11-17EMD MILLIPORE CORP
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202211060110.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2016-07-05
Filing Date
2017-02-20
Publication Date
2026-11-17
Estimated Expiration
2037-02-20

AI Technical Summary

Technical Problem

Existing programmable endonucleases suffer from poor accessibility and low specificity in targeted genome modification, especially with reduced activity in human cells and significant off-target effects.

Method used

By combining programmable DNA-modifying proteins with programmable DNA-binding proteins, and utilizing the binding sites of DNA-binding proteins near the target chromosome sequence, the accessibility and specificity of targeted DNA-modifying proteins are improved. CRISPR/Cas nuclease systems, zinc finger nucleases, and other technologies are used to combine non-nuclease modification domains for modification.

Benefits of technology

It improves the efficiency and specificity of targeted genome modification, reduces off-target effects, and enables effective genome and epigenetic modification in human cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 205694
    Figure 205694
  • Figure 327657
    Figure 327657
  • Figure 371212
    Figure 371212
Patent Text Reader

Abstract

Compositions and methods for using programmable DNA-binding proteins to increase the efficiency and / or specificity of targeted genome modifications or to facilitate the detection of specific genomic sites in eukaryotic cells.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This disclosure relates to compositions and methods for improving the efficiency and / or specificity of targeted genome modifications. Background Technology

[0002] Programmable endonucleases are increasingly becoming important tools for target genome engineering or modification in eukaryotes. Recently, RNA-guided clustered regularly spaced short palindromic repeats (CRISPR) / CRISPR-associated (Cas) systems have emerged as next-generation genome editing tools. Compared to previous generations of nucleases, such as zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), these new programmable endonucleases significantly enhance genome editing capabilities.

[0003] However, not all genomic targets can be effectively modified by these programmable endonucleases. In fact, some CRISPR-Cas endonucleases appear to have little or no activity in human cells. Chromatin structure, in particular, can be a barrier for these programmable endonucleases and prevent them from binding to target sequences. Therefore, there is a need to improve the accessibility of these programmable endonucleases to target sequences and / or increase the efficiency of targeted genomic modifications. Furthermore, there is a need to increase the specificity of targeted genomic modifications by reducing off-target effects. Summary of the Invention

[0004] Several aspects of this disclosure include a composition comprising (a) a programmable DNA-modifying protein or a nucleic acid encoding a programmable DNA-modifying protein and (b) at least one programmable DNA-binding protein or a nucleic acid encoding at least one programmable DNA-binding protein. Typically, the programmable DNA-modifying protein has nuclease activity (i.e., cleavage of both strands of a double-stranded sequence) or non-nuclease activity (e.g., epigenetic modification activity or transcriptional regulatory activity), and the at least one programmable DNA-binding protein lacks nuclease activity.

[0005] In embodiments where programmable DNA-modified proteins possess nuclease activity, for example, the programmable DNA-modified proteins can be selected from RNA-guided clustered regularly spaced short palindromic repeats (CRISPR) / CRISPR. Mutually CRISPR / Cas nuclease systems, CRISPR / Cas dual-nicking enzyme systems, zinc finger nucleases (ZFN), transcription activator-like effector nucleases (TALEN), meganucleases, fusion proteins and combinations thereof containing programmable DNA-binding domains linked to nuclease domains (i.e., generating double-strand DNA breaks).

[0006] In embodiments where the programmable DNA-modified protein has non-nuclease activity, for example, the programmable DNA-modified protein may be a fusion protein comprising a programmable DNA-binding domain linked to a non-nuclease-modified domain. In some embodiments, the programmable DNA-binding domain of the fusion protein may be a non-catalytically active CRISPR / Cas system, a wide range of non-catalytically active nucleases, zinc finger proteins, or transcription activator-like effectors, and the non-nuclease-modified domain of the fusion protein may have acetyltransferase activity, deacetylase activity, methyltransferase activity, demethylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity, deubiquitination activity, adenylation activity, deadenylation activity, SUMOylation activity, deSUMOylation activity, ribosylation activity, deribosylation activity, myristylation activity, demyristylation activity, citrullination activity, helicase activity, amination activity, deamination activity, alkylation activity, dealkylation activity, oxidation activity, transcriptional activation activity, or transcriptional repression activity. In specific implementation schemes, the non-nuclease-modified domains of the fusion protein have cytosine deaminase activity, histone acetyltransferase activity, transcriptional activation activity, or transcriptional repression activity.

[0007] According to certain embodiments of the compositions disclosed herein, the at least one programmable DNA-binding protein may be a catalytically inactive CRISPR / Cas system, a catalytically inactive wide range of nucleases, zinc finger proteins, transcription activator-like effectors, CRISPR / Cas nickases, ZFN nickases, TALEN nickases, or wide range of nuclease nickases.

[0008] Typically, the nucleic acid encoding a programmable DNA-modified protein and / or at least one programmable DNA-binding protein is mRNA or DNA. In some embodiments, the nucleic acid encoding a programmable DNA-modified protein and / or at least one programmable DNA-binding protein is part of a vector, such as a plasmid vector, lentiviral vector, adeno-associated virus vector, or adenovirus vector.

[0009] In specific embodiments, the programmable DNA-modified protein comprises a CRISPR / Cas nuclease system, a CRISPR / Cas dual-nicking enzyme system, or a non-catalytically inactive CRISPR / Cas system linked to a non-nuclease domain, and at least one programmable DNA-binding protein comprises a non-catalytically inactive CRISPR / Cas system, wherein each CRISPR / Cas system comprises a CRISPR / Cas protein and a guide RNA. In various embodiments, each CRISPR / Cas nuclease system may be a type I CRISPR / Cas system, a type II CRISPR / Cas system, a type III CRISPR / Cas system, or a type V CRISPR / Cas system. In some embodiments, each guide RNA may be at least partially chemically synthesized. In other embodiments, each guide RNA may be at least partially enzymatically synthesized. In a further embodiment, the nucleic acid encoding each CRISPR / Cas protein may be mRNA, and the nucleic acid encoding each guide RNA may be DNA. In other embodiments, the nucleic acid encoding each CRISPR / Cas protein may be mRNA, and the nucleic acid encoding each guide RNA may be DNA. In some respects, the nucleic acids encoding CRISPR / Cas proteins and / or the nucleic acids encoding guide RNA can be part of a vector, such as a plasmid vector, lentiviral vector, adeno-associated virus vector, or adenovirus vector.

[0010] Another aspect of this disclosure includes a kit that comprises any one or more of the compositions detailed above.

[0011] Another aspect of this disclosure provides a method for improving the efficiency and / or specificity of targeted genome modification in eukaryotic cells. The method includes introducing (a) a programmable DNA-modifying protein or a nucleic acid encoding a programmable DNA-modifying protein and (b) at least one programmable DNA-binding protein or a nucleic acid encoding at least one programmable DNA-binding protein into a eukaryotic cell. The programmable DNA-modifying protein targets a target chromosomal sequence, and each of the at least one programmable DNA-binding protein targets a site near the target chromosomal sequence. The binding of the at least one programmable DNA-binding protein to a site near the target chromosomal sequence improves the accessibility of the programmable DNA-modifying protein to the target chromosomal sequence, thereby improving the efficiency and / or specificity of targeted genome modification. The nearby binding site for each of the at least one programmable DNA-binding protein is located, for example, within about 250 base pairs on either side of the target chromosomal sequence. In some embodiments, the nearby binding site is less than about 200 bp or less than about 100 bp on either side of the target chromosomal sequence.

[0012] The programmable DNA-modifying protein used in the method may be a CRISPR / Cas nuclease system, a CRISPR / Cas dual-nicking enzyme system, a zinc finger nuclease (ZFN), a transcription activator-like effector nuclease (TALEN), a wide range of nucleases, a fusion protein containing a programmable DNA-binding domain linked to a nuclease domain, or a fusion protein containing a programmable DNA-binding domain linked to a non-nuclease domain. The programmable DNA-binding domain of the fusion protein can be a non-catalytically active CRISPR / Cas system, a wide range of non-catalytically active nucleases, zinc finger proteins, or transcription activator-like effectors. Furthermore, the non-nuclease-modified domains of the fusion protein can possess acetyltransferase activity, deacetylase activity, methyltransferase activity, demethylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity, deubiquitination activity, adenylation activity, deadenylation activity, SUMOylation activity, deSUMOylation activity, ribosylation activity, deribosylation activity, myristylation activity, demyristylation activity, citrullination activity, helicase activity, amination activity, deamination activity, alkylation activity, dealkylation activity, oxidation activity, transcriptional activation activity, or transcriptional repression activity. In a specific embodiment, the non-nuclease-modified domains of the fusion protein possess cytosine deaminase activity, histone acetyltransferase activity, transcriptional activation activity, or transcriptional repression activity.

[0013] The at least one programmable DNA-binding protein used in the method binds DNA but lacks nuclease activity (i.e., double-strand cleavage activity). In some embodiments, the at least one programmable DNA-binding protein may be a catalytically inactive CRISPR / Cas system, a catalytically inactive wide range of nucleases, zinc finger proteins, transcription activator-like effectors, CRISPR / Cas nickases, ZFN nickases, TALEN nickases, or wide range of nuclease nickases.

[0014] In a specific implementation, the programmable DNA-modifying protein comprises a CRISPR / Cas nuclease system, a CRISPR / Cas dual-nicking enzyme system, or a non-catalytically inactive CRISPR / Cas system linked to a non-nuclease domain, and the at least one programmable DNA-binding protein comprises a non-catalytically inactive CRISPR / Cas system, wherein each CRISPR / Cas system comprises a CRISPR / Cas protein and guide RNA.

[0015] In various embodiments, at least two, at least three, or more programmable DNA-binding proteins are introduced into eukaryotic cells. In specific embodiments, the eukaryotic cells are mammalian cells or human cells.

[0016] Another aspect of this disclosure includes a method for detecting chromosomal sequences or genomic loci in eukaryotic cells. The method includes introducing into a eukaryotic cell (a) a programmable DNA-binding protein comprising at least one detectable marker domain or a nucleic acid encoding a programmable DNA-binding protein comprising at least one detectable marker domain, and (b) at least one programmable DNA-binding protein or a nucleic acid encoding said at least one programmable DNA-binding protein, wherein the programmable DNA-binding protein comprising at least one detectable marker domain targets a target chromosomal sequence, and each of said at least one programmable DNA-binding protein targets a site near the target chromosomal sequence, wherein binding of said at least one programmable DNA-binding protein to a site near the target chromosomal sequence improves the accessibility of the programmable DNA-binding protein comprising at least one detectable marker domain to the target chromosomal sequence. The method may further include detecting the programmable DNA-binding protein comprising at least one detectable marker domain that binds to the target chromosomal sequence. The detection step can be performed in live or fixed cells and may involve, for example, dynamic live-cell imaging, fluorescence microscopy, confocal microscopy, immunofluorescence, immunoassay, RNA-protein binding, or protein-protein binding.

[0017] The programmable DNA-binding protein used in the detection method, comprising at least one detectable labeling domain, includes a programmable DNA-binding domain, which may be a non-catalytically active CRISPR / Cas system, a non-catalytically active broad-spectrum nuclease, a zinc finger protein, or a transcription activator-like effector. The at least one detectable labeling domain of the programmable DNA-binding protein may be, for example, a fluorescent protein, a fluorescent tag, an epitope tag, or a naturally occurring epitope within the programmable DNA-binding protein. In some embodiments, the programmable DNA-binding protein comprising at least one detectable labeling domain may further include non-nuclease modifications. The at least one programmable DNA-binding protein binds DNA but lacks nuclease activity (i.e., double-strand cleavage activity). In some embodiments, the programmable DNA-binding protein may be a non-catalytically active CRISPR / Cas system, a non-catalytically active broad-spectrum nuclease, a zinc finger protein, a transcription activator-like effector, a CRISPR / Cas nickase, a ZFN nickase, a TALEN nickase, or a broad-spectrum nuclease nickase. In a specific implementation, the programmable DNA-binding protein comprising at least one detectable label domain may be a non-catalytically active CRISPR / Cas system linked to at least one detectable label domain, and the at least one programmable DNA-binding protein may be a non-catalytically active CRISPR / Cas system.

[0018] Other aspects and features of this disclosure are described in detail below. Brief description of the attached diagram Figure 1 An illustration of one embodiment of the method disclosed herein is provided. The proximity binding of the programmable DNA-binding protein improves the accessibility of the target site to the programmable nuclease, thereby increasing the cleavage efficiency at the target site.

[0019] Figure 2 The binding of non-catalytically active SpCas9 (SpdCas9) to nearby sites demonstrates that it enhances the cleavage efficiency of FnCas9. The sequence presented at the top shows the relative positions of the FnCas9 target site and the SpdCas9 binding site at the POR locus. The bottom shows the results of the Cel-I nuclease assay.

[0020] Figure 3A The experimental design is shown to determine whether binding non-catalytically active SpCas9 (SpdCas9) increases epitope-tagged (i.e., FLAG-tagged) activity. ®- Accessibility and binding of the tagged (catalytically inactive) CjCas9 (CjdCas9) to previously inaccessible sites in the POR locus.

[0021] Figure 3B A diagram of a chromatin immunoprecipitation binding assay is provided, which is used to detect the binding of epitope-tagged CjdCas9 to target sites in the POR and AAVS1 loci.

[0022] Figure 3C The study showed that the binding of SpdCas9 to nearby sites enhanced the binding of epitope-tagged CjCas9 to previously inaccessible sites in the POR locus.

[0023] Figure 4 The binding of non-catalytically active SpCas9 (SpdCas9) to nearby sites demonstrates that it enhances the cleavage efficiency of CjCas9. The sequence presented at the top shows the relative positions of the CjCas9 target site and the SpdCas9 binding site at the POR locus. The results of Cel-I nuclease assays are shown at the bottom.

[0024] Figure 5 The binding of non-catalytically active SpCas9 (SpdCas9) to nearby sites demonstrates that it enhances the cleavage efficiency of FnCpf1. The top shows the relative positions of the FnCpf1 target site and the SpdCas9 binding site at the POR locus, and the bottom shows the results of the Cel-I nuclease assay.

[0025] Figure 6The binding of non-catalytically active SpCas9 (SpdCas9) to nearby sites demonstrates enhanced specific cleavage of CjCas9. The target sites of CjCas9 in the HBD and HBB loci, and the binding site of SpdCas9 in the HBB locus, are shown at the top. Results of Cel-I nuclease assays are shown at the bottom.

[0026] Figure 7 The binding of the catalytically inactive FnCas9 (FndCas9) to nearby sites demonstrates that it enhances the specificity of SpCas9 cleavage. The top shows the relative positions of the SpoSas9 target site and the FndCas9 binding site at the POR locus. The bottom shows the results of the Cel-I nuclease assay.

[0027] Figure 8 Enhancement of ssDNA oligonucleotide-mediated gene editing is shown. The top shows the relative positions of the target site and ssDNA oligonucleotide sequence in the POR locus. The bottom shows the results of EcoRI site-targeted integration. EcoRI site integration efficiency (%) was determined by ImageJ. M: Broad range of DNA markers. ND: Not determined. Invention Details This disclosure provides compositions and methods for improving the accessibility of chromosomal DNA to targeted endonucleases and other programmable DNA modification proteins, wherein the improved accessibility leads to increased efficiency and / or specificity of targeted genomic or epigenetic modifications. Some CRISPR / Cas endonucleases have been found to have reduced or no activity in human cells. Nucleosome occupancy, localization, and how the DNA sequence is wrapped around histone octamers can determine the degree of accessibility of that sequence to DNA-binding proteins (Chereji et al., Briefing Functional Genomics, 2014, 14:506-60). Therefore, in the apparent inactivation of many CRISPR / Cas endonucleases in human cells, barriers imposed by local chromatin conformation may play a role. As detailed herein, it has been found that binding of DNA-binding proteins to sites near the target site of targeted DNA modification proteins (i.e., within approximately 250 base pairs) improves the accessibility of the targeted DNA modification proteins to said target site, thereby improving the efficiency and / or specificity of targeted genomic or epigenetic modifications. Therefore, the compositions and methods disclosed herein enable efficient targeted genomic / epigmatic modifications using CRISPR / Cas endonucleases previously thought to be inactivated in human cells. Furthermore, the compositions and methods disclosed herein improve selective genomic modifications between nearly identical target sites, thereby reducing off-target effects.

[0028] Composition One aspect of this disclosure provides a composition comprising (a) a programmable DNA-modifying protein or a nucleic acid encoding a programmable DNA-modifying protein and (b) at least one programmable DNA-binding protein or a nucleic acid encoding at least one programmable DNA-binding protein. The programmable DNA-modifying protein is detailed in section (I)(a) below, the programmable DNA-binding protein is detailed in section (I)(b) below, and the nucleic acid encoding these proteins is detailed in section (I)(c) below.

[0029] Programmable DNA Modified Proteins Programmable DNA-modifying proteins are proteins that bind to specific target sequences in chromosomal DNA and modify DNA or DNA-related proteins at or near the target sequence. Therefore, programmable DNA-modifying proteins contain both DNA-binding domains and catalytically modifying domains.

[0030] The DNA-binding domain is programmable because it can be designed or engineered to recognize and bind different DNA sequences. In some embodiments, DNA binding is mediated by an interaction between the protein and the target DNA. Therefore, the DNA-binding domain can be programmed through protein engineering to bind the target DNA sequence. In other embodiments, DNA binding is mediated by a guide RNA that interacts with the programmable DNA-binding domain of the protein and the target DNA. In this case, by designing a suitable guide RNA, the programmable DNA-binding domain can target the target DNA sequence.

[0031] Programmable DNA-modifying proteins may contain a variety of modification domains. In some embodiments, the modification domain is a nuclease domain that has nuclease activity and cleaves both strands of a double-stranded DNA sequence (i.e., generates a double-strand break). The double-strand break can then be repaired by cellular DNA repair processes such as non-homologous end joining (NHEJ) or homologous directed repair (HDR). Thus, DNA sequences can be modified by deletions, insertions, and / or substitutions of at least one base pair up to, for example, thousands of base pairs. Examples of programmable DNA-modifying proteins containing nuclease domains include, but are not limited to, CRISPR / Cas nuclease systems, CRISPR / Cas dual-nicking enzyme systems, zinc finger nucleases, transcription activator-like effector nucleases, large-scale nucleases, fusion proteins containing nuclease domains linked to programmable DNA-binding domains, and combinations thereof. Programmable DNA-modifying proteins containing nuclease domains are detailed in sections (I)(a)(i)-(vi) below.

[0032] In other embodiments, the modification domain of the programmable DNA-modifying protein has non-nuclease activity (e.g., epigenetic modification activity or transcriptional regulatory activity), such that the programmable DNA-modifying protein modifies the structure and / or activity of DNA and / or DNA-related proteins. Therefore, the programmable DNA-modifying protein is a fusion protein comprising a non-nuclease-modifying domain linked to a programmable DNA-binding domain. These proteins are described in detail in sections (I)(a)(vii) below.

[0033] The programmable DNA-modified protein may include wild-type or naturally occurring DNA binding and / or modification domains, modified forms of naturally occurring DNA binding and / or modification domains, synthetic or artificial DNA binding and / or modification domains, and combinations thereof.

[0034] (i) CRISPR / Cas nuclease system In some embodiments, the programmable DNA-modifying protein may be an RNA-directed CRISPR / Cas nuclease system that introduces double-strand breaks into DNA. The CRISPR / Cas nuclease system comprises a CRISPR / Cas nuclease and guide RNA.

[0035] CRISPR / Cas nucleases. In some implementations, CRISPR / Cas nucleases may be derived from type I (i.e., IA, IB, IC, ID, IE, or IF), type II (i.e., IIA, IIB, or IIC), type III (i.e., IIIA or IIIB), or type V CRISPR systems present in various bacteria and archaea. For example, the CRISPR / Cas system can be derived from *Streptococcus* sp. (e.g., *Streptococcus pyogenes*), *Campylobacter* sp. (e.g., *Campylobacter jejuni*), *Francisella* sp. (e.g., *Francisella novicida*), *Acaryochloris* sp., *Acetohalobium* sp., *Acidaminococcus* sp., *Acidithiobacillus* sp., *Alicyclobacillus* sp., *Allochromatium* sp., *Ammonifex* sp., *Anabaena* sp., *Arthrospira* sp., *Bacillus* sp., and *Burkholderiales*. sp.), Caldicelulosiruptor sp., Candidatus sp., Clostridium sp., Crocosphaera sp., Cyanothece sp., Exiguobacterium sp., Finegoldia sp., Ktedonobacter sp., Lachnospiraceae sp., Lactobacillus sp., Lyngbya sp., Marinobacter sp., Methanohalobium sp., Microscilla sp., Microcoleus sp., Microcystis sp., Natranaerobius sp., Neisseria sp.), Nitrosococcus sp., Nocardiopsis sp., Nodularia sp., Nostoc sp., Oscillatoria sp., Polaromonas sp., Pelotomaculum sp., Pseudoalteromonas sp., Petrotoga sp., Prevotella sp., Staphylococcus sp., Streptomyces sp., Streptosporangium sp., Synechococcus sp., Thermosipho sp., or Verrucomicrobia sp. In other implementations, the CRISPR / Cas nuclease may be derived from an archaic CRISPR system, a CRISPR-CasX system, or a CRISPR-CasY system (Burstein et al., Nature, 2017, 542(7640):237-241).

[0036] In one specific embodiment, the CRISPR / Cas nuclease may be derived from a type I CRISPR / Cas system. In another specific embodiment, the CRISPR / Cas nuclease may be derived from a type II CRISPR / Cas system. In yet another specific embodiment, the CRISPR / Cas nuclease may be derived from a type III CRISPR / Cas system. In yet another specific embodiment, the CRISPR / Cas nuclease may be derived from a type V CRISPR / Cas system.

[0037] Non-limiting examples of suitable CRISPR proteins include Cas proteins, Cpf proteins, C2c proteins (e.g., C2c1, C2c2, Cdc3), Cmr proteins, Csa proteins, Csb proteins, Csc proteins, Cse proteins, Csf proteins, Csm proteins, Csn proteins, Csx proteins, Csy proteins, Csz proteins, and their derivatives or variants. In a specific embodiment, the CRISPR / Cas nuclease may be a type II Cas9 protein, a type V Cpf1 protein, or a derivative thereof.

[0038] In some embodiments, the CRISPR / Cas nuclease may be *Streptococcus pyogenes* Cas9 (SpCas9) or *Streptococcus thermophilus* Cas9 (StCas9). In other embodiments, the CRISPR / Cas nuclease may be *Campylobacter jejuni* Cas9 (CjCas9). In still other embodiments, the CRISPR / Cas nuclease may be *Francis microbiota* Cas9 (FnCas9). In yet another embodiment, the CRISPR / Cas nuclease may be *Neisseria griseus* (…). Neisseria cinerea Cas9 (NcCas9). In a further embodiment, the CRISPR / Cas nuclease may be the novel culprit Francisella Cpf1 (FnCpf1), Aminococcus Cpf1 (AsCpf1), or Helicobacter ND2006 Cpf1 (LbCpf1).

[0039] Typically, the CRISPR / Cas nuclease includes RNA recognition and / or RNA binding domains that interact with guide RNA. The CRISPR / Cas nuclease also includes at least one nuclease domain with endonuclease activity. For example, the Cas9 protein includes a RuvC-like nuclease domain and an HNH-like nuclease domain, and the Cpf1 protein includes a RuvC-like domain. CRISPR / Cas nucleases may also include DNA-binding domains, helicase domains, RNase domains, protein-protein interaction domains, dimerization domains, and other domains.

[0040] The CRISPR / Cas nuclease may further include at least one nuclear localization signal, a cell penetration domain, and / or a labeling domain. Non-limiting examples of nuclear localization signals include PKKKRKV (SEQ ID NO:1), PKKKRRV (SEQ ID NO:2), KRPAATKKAGQAKKKK (SEQ ID NO:3), YGRKKRRQRRR (SEQ ID NO:28), RKKRRQRRR (SEQ ID NO:29), PAAKRVKLD (SEQ ID NO:30), RQRRNELKRSP (SEQ ID NO:31), VSRKRPRP (SEQ ID NO:32), PPKKARED (SEQ ID NO:33), PQPKKKPL (SEQ ID NO:34), SALIKKKKKMAP (SEQ ID NO:35), PKQKKRK (SEQ ID NO:36), RKLKKKIKKL (SEQ ID NO:37), REKKKFLKRR (SEQ ID NO:38), KRKGDEVDGVDEVAKKKSKK (SEQ ID NO:38). NO:39), RKCLQAGMNLEARKTKK (SEQ ID NO:40), NQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY (SEQ ID NO:41), and RMRIZFKNKGKDTAELRRRRVEVSVELRKAKKDEQILKRRNV (SEQ ID NO:42).Non-restricted examples of suitable cell-penetrating domains include GRKKRRQRRRPPQPKKKRKV (SEQ ID NO:4), PLSSIFSRIGDPPKKKRKV (SEQ ID NO:5), GALFLGWLGAAGSTMGAPKKKRKV (SEQ ID NO:6), GALFLGFLGAAGSTMGAWSQPKKKRKV (SEQ ID NO:7), KETWWETWWTEWSQPKKKRKV (SEQ ID NO:8), YARAAARQARA (SEQ ID NO:43), THRLPRRRRRR (SEQ ID NO:44), GGRRARRRRRR (SEQ ID NO:45), RRQRRTSKLMKR (SEQ ID NO:46), GWTLNSAGYLLGKINLKALAALAKKIL (SEQ ID NO:47), KALAWEAKLAKALAKALAKHLAKALAKALKCEA (SEQ ID NO:48), and RQIKIWFQNRRMKWKK (SEQ ID NO:48). NO:49). The labeled domain includes the fluorescent protein and the purified or epitope tag. Suitable fluorescent proteins include, but are not limited to, green fluorescent proteins (e.g., GFP, eGFP, GFP-2, tagGFP, turboGFP, Emerald, Azami Green, Monomeric Azami Green, CopGFP, AceGFP, ZsGreen1), yellow fluorescent proteins (e.g., YFP, EYFP, lemon yellow, Venus, YPet, PhiYFP, ZsYellow1), blue fluorescent proteins (e.g., BFP, EBFP, EBFP2, azurite, mKalama1, GFPuv, sapphire, T-sapphire), and cyan fluorescent proteins (e.g., ECFP, Cerulean, CyPet, ...). (AmCyan1, Midoriishi-Cyan), red fluorescent proteins (e.g., mKate, mKate2, mPlum, DsRed monomer, mCherry, mRFP1, DsRed-Express, DsRed2, DsRed-monomer, HcRed-Tandem, HcRed1, AsRed2, eqFP611, mRasberry, mStrawberry, Jred), and orange fluorescent proteins (e.g., mOrange, mKO, Kusabira-Orange, MonomericKusabira-Orange, mTangerine, tdTomato). Non-limiting examples of suitable purification or epitope tags include 6xHis and FLAG. ®HA, GST, Myc, etc.

[0041] The nuclear localization signal, cell-penetrating domain, and / or labeling domain may be located at the N-terminus, C-terminus, or internal location of the protein. In some embodiments, the CRISPR / Cas nuclease may also contain at least one detectable label. The detectable label may be a fluorophore (e.g., FAM, TMR, Cy3, Cy5, Texas Red, Oregon Green, Alexa Fluors, Halo tags, or suitable fluorescent tags / dyes), a chromophore (e.g., biotin, digoxigenin, etc.), a quantum dot, or a gold particle. The detectable label can be attached to any amino acid of the protein using conventional methods.

[0042] Guide RNA. The CRISPR / Cas nuclease system also includes guide RNA (gRNA). The guide RNA interacts with the CRISPR / Cas nuclease and the target site to guide the CRISPR / Cas nuclease to the target site in the chromosomal sequence. The target site is not sequence-restricted except for the adjacent prespacer motif (PAM). For example, the PAM sequence of the Cas9 protein includes 3'-NGG, 3'-NGGNG, 3'-NNAGAAW, and 3'-ACAY, and the PAM sequence of Cpf1 includes 5'-TTN (where N is defined as any nucleotide, W is defined as A or T, and Y is defined as C or T).

[0043] Each guide RNA may contain three regions: a first region at the 5' end complementary to the target site in the chromosomal DNA sequence, a second region internal and forming a stem-loop structure, and a third region at the 3' end that remains essentially single-stranded. The second and third regions form secondary structures that interact with CRISPR / Cas proteins. The first region is different for each guide RNA (i.e., sequence-specific). The second and third regions may be the same in the guide RNA, which forms a complex with a specific CRISPR / Cas protein.

[0044] The first region of the guide RNA is complementary to the sequence at the target site (i.e., the prespacer sequence), allowing the first region of the guide RNA to pair with the bases of the target sequence. For example, the first region of the SpCas9 guide RNA may contain GN. 17 - 20GG. Typically, the complementarity between the first region of the guide RNA (i.e., crRNA) and the target sequence is at least 80%, at least 85%, at least 90%, at least 95%, or more. In various embodiments, the first region of the guide RNA may contain about 10 nucleotides or more than about 25 nucleotides. For example, the base-pairing region between the first region of the guide RNA and the target site in the cDNA sequence may be about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 23, 24, 25, or more nucleotides in length. In one exemplary embodiment, the first region of the guide RNA is about 19, 20, or 21 nucleotides in length.

[0045] The guide RNA also includes a second region forming a secondary structure. In some embodiments, the secondary structure comprises at least one stem (or hairpin) and loop. The length of each loop and stem can vary. For example, the length of a loop can be from about 3 to about 10 nucleotides, and the length of a stem can be from about 6 to about 20 base pairs. The stem may contain one or more protrusions of about 1 to about 10 nucleotides. Therefore, the total length of the second region can be from about 16 to about 60 nucleotides. The guide RNA also includes a third region at its 3' end, which remains essentially single-stranded. Therefore, the third region is not complementary to any nucleic acid sequence in the target cell, and is not complementary to the rest of the guide RNA. The length of the third region can vary. Typically, the length of the third region is greater than about 4 nucleotides. For example, the length of the third region can be from about 5 to about 60 nucleotides.

[0046] The combined length of the second and third regions (also known as the universal or scaffold regions) of the guide RNA can be from about 30 to about 120 nucleotides. In one aspect, the combined length of the second and third regions of the guide RNA is from about 70 to about 100 nucleotides.

[0047] In other embodiments, the second and third regions of the guide RNA may include one or more additional stem-loop regions, wherein the stem-loop regions contain aptamer sequences (Konermann et al., Nature3, 2015, 517(7536):583-588; Zalatan et al., Cell, 2015, 160(1-2):339-50). Suitable aptamer sequences include sequences that bind to adaptor proteins selected from the following: MS2, PP7, COM, Qβ, F2, GA, fr, JP501, M12, R17, BZ13, JP34, JP500, KU1, M11, MX1, TW18, VK, SP, FI, ID2, NL95, TW19, AP205, φCb5, φCb8r, φCb12r, φCb23r, 7s, PRR1, HSF1, AID, APOBEC1, p300, TET1 / 2 / 3, VP64, GFP, Rta, p65, MyoD1, or VP160. In these implementations, the total length of the second and third regions of the guide RNA can range from about 125 nucleotides, about 150 nucleotides, about 175 nucleotides, about 200 nucleotides, about 225 nucleotides, about 250 nucleotides, about 275 nucleotides, or about 300 nucleotides.

[0048] In some embodiments, the guide RNA may be a single molecule containing all three regions. In other embodiments, the guide RNA may comprise two separate molecules. The first RNA molecule (i.e., crRNA) may contain the first region of the guide RNA and half of the "stem" of the second region of the guide RNA. The second RNA molecule (i.e., tracrRNA) may contain the other half of the "stem" of the second region of the guide RNA and the third region of the guide RNA. Thus, in this embodiment, each of the first and second RNA molecules contains a nucleotide sequence complementary to each other. For example, in one embodiment, the crRNA and tracrRNA RNA molecules each contain a sequence (about 6 to about 20 nucleotides) that pairs with another sequence to form a functional guide RNA. For example, the guide RNA of a type II CRISPR / Cas system may comprise crRNA and tracrRNA. In some aspects, the crRNA of a type II CRISPR / Cas system can be chemically synthesized, and the tracrRNA type II CRISPR / Cas system can be synthesized in vitro (see section (I)(c) below). In other embodiments, the guide RNA of a type V CRISPR / Cas system may comprise only crRNA.

[0049] Guide RNA may comprise standard ribonucleotides, modified ribonucleotides (e.g., pseudouridine), ribonucleotide isomers, and / or ribonucleotide analogs. In some embodiments, the guide RNA may also comprise at least one detectable marker. The detectable marker may be a fluorophore (e.g., FAM, TMR, Cy3, Cy5, Texas Red, Oregon Green, Alexa Fluors, Halo tags, or suitable fluorescent dyes), a chromophore (e.g., biotin, digoxigenin, etc.), quantum dots, or gold particles. Those skilled in the art are familiar with gRNA design and construction; for example, gRNA design tools are available from the Internet or commercial sources.

[0050] Guide RNA can be synthesized chemically, enzymatically, or in combination thereof. For example, guide RNA can be synthesized using a solid-phase synthesis method based on standard phosphoramide. Alternatively, guide RNA can be synthesized in vitro by operatively linking DNA encoding the guide RNA to a promoter control sequence recognized by a phage RNA polymerase. Examples of suitable phage promoter sequences include the T7, T3, SP6 promoter sequences or variants thereof. In embodiments where the guide RNA comprises two separate molecules (i.e., crRNA and tracrRNA), crRNA can be chemically synthesized and tracrRNA can be enzymatically synthesized. The nucleic acid encoding the guide RNA can be part of a plasmid vector, which may further contain other expression control sequences (e.g., enhancer sequences, Kozak sequences, polyadenylation sequences, transcription termination sequences, etc.), selection marker sequences (e.g., antibiotic resistance genes), origin of replication, etc.). As detailed in sections (I)(c) below, the nucleic acid encoding the guide RNA can be operatively linked to a promoter control sequence recognized by RNA polymerase III (PolIII) for expression in eukaryotic cells.

[0051] (ii) CRISPR / Cas dual-cut enzyme system In other embodiments, the programmable DNA-modifying protein may be a CRISPR / Cas dual-nicking enzyme system. The CRISPR / Cas dual-nicking enzyme system is similar to the CRISPR / Cas nuclease system described in sections (I)(a)(i) above, except that the CRISPR / Cas nuclease is modified to cleave only one DNA strand. Therefore, a single CRISPR / Cas nicking enzyme system produces single-strand breaks or nicks in double-stranded DNA, while a paired CRISPR / Cas dual-nicking enzyme system containing paired offset guide RNA produces double-strand breaks in DNA.

[0052] CRISPR / Cas nucleases can be converted into nicking enzymes through one or more mutations and / or deletions. For example, Cas9 nicking enzymes can contain one or more mutations in one of the nuclease domains (e.g., a RuvC-like domain or an HNH-like domain). For example, the one or more mutations could be D10A, D8A, E762A, and / or D986A in the RuvC-like domain, or the one or more mutations could be H840A, H559A, N854A, N856A, and / or N863A in the HNH-like domain.

[0053] (iii) Zinc finger nucleases In other embodiments, the programmable DNA-modifying protein may be a zinc finger nuclease (ZFN). A ZFN comprises a DNA-binding zinc finger region and a nuclease domain. The zinc finger region may include approximately two to seven zinc fingers, for example, approximately four to six zinc fingers, each binding three nucleotides. The zinc finger region can be modified to recognize and bind any DNA sequence. Zinc finger design tools or algorithms are available from the Internet or commercial sources. The zinc fingers can be linked together using suitable adapter sequences.

[0054] ZFN also includes a nuclease domain, which can be obtained from any endonuclease or exonuclease. Non-restrictive examples of endonucleases from which the nuclease domain can be derived include, but are not limited to, restriction endonucleases and homing endonucleases. In some embodiments, the nuclease domain can be derived from type II-S restriction endonucleases. Type II-S endonucleases typically cleave DNA at sites a few base pairs from the recognition / binding site, thus having separable binding and cleavage domains. These enzymes are typically monomers that can transiently associate to form dimers to cleave each DNA strand at staggered positions. Non-restrictive examples of suitable II-S endonucleases include BfiI, BpmI, BsaI, BsgI, BsmBI, BsmI, BspMI, FokI, MboII, and SapI. In some embodiments, the nuclease domain can be the FokI nuclease domain or a derivative thereof. The type II-S nuclease domain can be modified to promote dimerization of two different nuclease domains. For example, the cleavage domain of FokI can be modified by mutating certain amino acid residues. As non-limiting examples, amino acid residues at positions 446, 447, 479, 483, 484, 486, 487, 490, 491, 496, 498, 499, 500, 531, 534, 537, and 538 of the FokI nuclease domain are targets for modification. For example, a modified FokI domain may contain the Q486E, I499L, and / or N496D mutations, and other modified FokI domains may contain the E490K, I538K, and / or H537R mutations.

[0055] The ZFN may further include at least one nuclear localization signal, a cell penetration domain and / or a labeling domain, as described in sections (I)(a)(i) above.

[0056] (iv) Transcription activator-like effector nucleases In an alternative embodiment, the programmable DNA-modifying protein may be a transcription activator-like effector nuclease (TALEN). TALEN contains a DNA-binding domain consisting of highly conserved repetitive sequences derived from transcription activator-like effectors (TALEs) linked to the nuclease domain. TALEs are proteins secreted by the plant pathogen Xanthomonas to alter gene transcription in host plant cells. TALE repeat arrays can be engineered through modular protein design to target any target DNA sequence. The nuclease domain of the TALEN may be any nuclease domain as described in sections (I)(a)(iii) above. In a specific embodiment, the nuclease domain is derived from FokI (Sanjana). et al ., 2012, Nat Protoc, 7(1):171-192).

[0057] TALEN may also include at least one nuclear localization signal, cell penetration domain, labeling domain and / or detectable label, as described in sections (I)(a)(i) above.

[0058] (v) Wide-range nucleases or rare-cut endonucleases In other embodiments, the programmable DNA-modifying protein may be a large-scale nuclease or a derivative thereof. Large-scale nucleases are endonucleases characterized by long recognition sequences, typically ranging from about 12 to about 45 base pairs. Due to this requirement, the recognition sequence usually appears only once in any given genome. Among large-scale nucleases, the homing endonuclease family, named LAGLIDADG, has become a valuable tool for genome and genome engineering research. In some embodiments, the large-scale nuclease may be I-SceI, I-TevI, or variants thereof. By modifying its recognition sequence using techniques well known to those skilled in the art, the large-scale nuclease can be targeted to specific chromosomal sequences.

[0059] In an alternative embodiment, the programmable DNA-modifying protein may be a rare-cut endonuclease nucleus or a derivative thereof. Rare-cut endonucleases are site-specific endonucleases whose recognition sequences are rarely found in the genome, preferably only once. Rare-cut endonucleases may recognize 7-nucleotide sequences, 8-nucleotide sequences, or longer recognition sequences. Non-limiting examples of rare-cut endonucleases include NotI, AscI, PacI, AsiSI, SbfI, and FseI.

[0060] The wide range of nucleases or rare nucleases may also include at least one nuclear localization signal, a cell penetration domain, a labeling domain and / or a detectable label, as described in sections (I)(a)(i) above.

[0061] (vi) Programmable fusion proteins containing nuclease domains In another embodiment, the programmable DNA-modified protein may be a fusion protein comprising a programmable DNA-binding domain linked to a (double-stranded) nuclease domain. The nuclease domain of the fusion protein may be any nuclease domain described in sections (I)(a)(iii) above, a nuclease domain derived from a CRISPR / Cas nuclease (e.g., a RuvC-like or HNH-like nuclease domain of Cas9 or a nuclease domain of Cpf1), or a nuclease domain derived from a wide range of nucleases or rare endonucleases.

[0062] The programmable DNA-binding domain of the fusion protein can be a modified programmable endonuclease (i.e., a CRISPR / Cas nuclease or a broad range of nucleases) lacking all nuclease activities. Therefore, the DNA-binding domain of the fusion protein can be a catalytically inactive CRISPR / Cas system or a catalytically inactive broad range of nucleases. Alternatively, the programmable DNA-binding domain of the fusion protein can be a programmable DNA-binding protein, such as a zinc finger protein or a transcription activator-like effector. In some embodiments, the programmable DNA-binding domain can be a catalytically inactive CRISPR / Cas nuclease, wherein nuclease activity is removed through mutation and / or deletion. For example, the catalytically inactive CRISPR / Cas protein can be a catalytically inactive (dead) Cas9 (dCas9), wherein the RuvC-like domain contains D10A, D8A, E762A, and / or D986A mutations, and the HNH-like domain contains H840A, H559A, N854A, N865A, and / or N863A mutations. Alternatively, the catalytically inactive CRISPR / Cas protein may be a catalytically inactive (dead) Cpf1 protein containing a comparable mutation in its nuclease domain. In other embodiments, the programmable DNA-binding domain may be a catalytically inactive broad-spectrum nuclease, wherein nuclease activity is removed by mutation and / or deletion; for example, a catalytically inactive broad-spectrum nuclease may contain a C-terminal truncation.

[0063] The fusion protein containing nuclease activity may also contain at least one nuclear localization signal, a cell penetration domain, a labeling domain and / or a detectable label, as described in sections (I)(a)(i) above.

[0064] (vii) Programmable fusion proteins / complexes containing non-nuclease domains In an alternative embodiment, the programmable DNA-modified protein may be a fusion protein comprising a programmable DNA-binding domain linked to a non-nuclease-modifying domain. Suitable programmable DNA-binding domains are described in sections (I)(a)(vi) above.

[0065] In some implementations, the non-nuclease-modified domain may be an epigenetic modification domain that alters the structure of DNA or chromatin (and may or may not alter the DNA sequence). Non-limiting examples of suitable epigenetic modification domains include epigenetic modification domains having DNA methyltransferase activity (e.g., cytosine methyltransferase), DNA demethylase activity, DNA deamination (e.g., cytosine deaminase, adenosine deaminase, guanine deaminase), DNA amination, DNA helicase activity, histone acetyltransferase (HAT) activity (e.g., HAT domain derived from E1A-binding protein p300), histone deacetylase activity, histone methyltransferase activity, histone demethylase activity, histone kinase activity, histone phosphatase activity, histone ubiquitin ligase activity, histone deubiquitination activity, histone adenylation activity, histone deacetylation activity, histone SUMOylation activity, histone deSUMOylation activity, histone ribosylation activity, histone deribosylation activity, histone myristylation activity, histone demyristylation activity, histone citrullination activity, histone alkylation activity, histone dealkylation activity, or histone oxidation activity. In a specific implementation, the epigenetic modification domain may include cytosine deaminase activity, histone acetyltransferase activity, or DNA methyltransferase activity.

[0066] In other embodiments, the non-nuclease-modified domain may be a transcriptional activation domain or a transcriptional repression domain. Suitable transcriptional activation domains include, but are not limited to, the herpes simplex virus VP16 domain, VP64 (which is a tetrameric derivative of VP16), VP160, NFκB p65 activation domain, p53 activation domains 1 and 2, CREB (cAMP response element binding protein) activation domain, E2A activation domain, activation domains derived from human heat shock factor 1 (HSF1), or NFAT (nuclear factor for activated T cells) activation domain. Non-limiting examples of suitable transcriptional repression domains include the inducible early cAMP repressor (ICER) domain, the Kruppel-associated box A (KRAB-A) repression domain, the YY1 glycine-rich repression domain, Sp1-like repressors, E(spl) repressors, IκB repressors, or MeCP2. Transcriptional activation or repression domains can fuse with DNA-binding proteins on genes or bind through non-covalent protein-protein, protein-RNA, or protein-DNA interactions.

[0067] In implementations of programmable DNA-modified proteins that incorporate a CRISPR / Cas system, the guide RNA of the CRISPR / Cas system may contain an aptamer sequence that binds to a transcription activator, transcription repressor, or epigenetic modifying protein (Konerman et al., Nature, 2015, 517(7536):583-588; Zalatan et al., Cell, 2015, 160(1-2):339-50).

[0068] The fusion protein containing non-nuclease activity may also contain at least one nuclear localization signal, a cell penetration domain, a labeling domain and / or a detectable label, as described in sections (I)(a)(i) above.

[0069] (b) Programmable DNA-binding proteins The composition further comprises at least one programmable DNA-binding protein. A programmable DNA-binding protein is a protein that binds to a specific DNA sequence but does not modify the DNA or DNA-related proteins.

[0070] In some embodiments, the at least one programmable DNA-binding protein may be a modified CRISPR / Cas nuclease lacking nuclease activity. For example, the programmable DNA-binding protein may be a catalytically inactive CRISPR / Cas system. For this purpose, the CRISPR / Cas nuclease may be modified by mutation and / or deletion to remove all nuclease activity. In one embodiment, both the RuvC-like domain and the HNH-like domain contain one or more mutations and / or deletions to remove nuclease activity. For example, the catalytically inactive CRISPR / Cas protein may be a catalytically inactive (dead)Cas9 (dCas9), wherein the RuvC-like domain contains D10A, D8A, E762A, and / or D986A mutations, and the HNH-like domain contains H840A, H559A, N854A, N856A, and / or N863A mutations. Alternatively, the catalytically inactive CRISPR / Cas protein may be a catalytically inactive (dead)Cpf1 protein containing comparable mutations in the nuclease domains. In other respects, the programmable DNA-binding protein may be a CRISPR / Cas protein modified to cleave one strand of a double-stranded sequence (i.e., a cleavage enzyme), as detailed in sections (I)(a)(ii) above.

[0071] In other embodiments, the at least one programmable DNA-binding protein may be a non-catalytically active broad-spectrum nuclease, wherein nuclease activity is removed by mutation and / or deletion; for example, a non-catalytically active broad-spectrum nuclease may contain a C-terminal truncation. In other embodiments, the at least one programmable DNA-binding protein may be a zinc finger protein or a transcription activator-like effector (TALE). In yet another embodiment, the at least one programmable DNA-binding protein may be a CRISPR / Cas nickase, a ZFN nickase, a TALEN nickase, or a broad-spectrum nuclease nickase. ZFN, TALEN, and broad-spectrum nuclease nickases contain mutations and / or deletions in one of the nuclease domains or hemidomains, such that the nickase cleaves only one strand of the double-stranded sequence.

[0072] The programmable DNA-binding protein may also include at least one nuclear localization signal, a cell penetration domain, a labeling domain, and / or a detectable label, as described in sections (I)(a)(i) above.

[0073] (c) Nucleic acids encoding programmable DNA-modified proteins or programmable DNA-binding proteins The nucleic acid encoding the programmable DNA-modified protein described in section (I)(a) above, or the programmable DNA-binding protein described in section (I)(b) above, can be DNA or RNA, can be linear or circular, and can be single-stranded or double-stranded. The RNA or DNA can be codon-optimized for efficient translation into a protein in the target eukaryotic cell. The codon optimization program is available as free software or from commercial sources.

[0074] In some embodiments, the nucleic acid encoding the programmable DNA-modified protein or the at least one programmable DNA-binding protein may be mRNA. The mRNA may be synthesized in vitro. For this purpose, the DNA encoding the DNA-modified protein or at least one DNA-binding protein may be operatively linked to a promoter sequence recognized by a bacteriophage RNA polymerase for in vitro mRNA synthesis. For example, the promoter sequence may be a T7, T3, or SP6 promoter sequence or a variant of the T7, T3, or SP6 promoter sequence. In these embodiments, the in vitro transcribed RNA may be purified, capped, and / or polyadenylated. As detailed below, the DNA encoding the DNA-modified protein or DNA-binding protein may be part of a vector.

[0075] In other embodiments, the nucleic acid encoding a programmable DNA-modified protein or at least one programmable DNA-binding protein may be DNA. The DNA sequence encoding the programmable DNA-modified protein or at least one programmable DNA-binding protein may be operatively linked to at least one promoter control sequence for expression in target cells. In some embodiments, the DNA encoding sequence may also be linked to a polyadenylation signal (e.g., SV40 polyA signal, bovine growth hormone (BGH) polyA signal, etc.) and / or at least one transcription termination sequence.

[0076] In some embodiments, the DNA coding sequence may be operatively linked to a promoter sequence for expressing DNA-modifying or DNA-binding proteins in bacterial (e.g., *Escherichia coli*) or eukaryotic (e.g., yeast, insect, or mammalian) cells. Suitable bacterial promoters include, but are not limited to, the T7 promoter, the lac operon promoter, the trp promoter, the tac promoter (which is a hybrid of the trp and lac promoters), any variants of the foregoing, and any combination thereof. Non-limiting examples of suitable eukaryotic promoters include constitutive, regulatory, or cell- or tissue-specific promoters. Suitable eukaryotic constitutive promoter control sequences include, but are not limited to, the cytomegalovirus immediate early promoter (CMV), the simian virus (SV40) promoter, the adenovirus major late promoter, the Raoul's sarcoma virus (RSV) promoter, the mouse mammary tumor virus (MMTV) promoter, the glycerol phosphokinase (PGK) promoter, the elongation factor (ED1)-α promoter, the ubiquitin promoter, the actin promoter, the microtubule promoter, the immunoglobulin promoter, fragments thereof, or any combination thereof. Examples of suitable eukaryotic regulatory promoter control sequences include, but are not limited to, promoter control sequences regulated by heat shock, metals, steroids, antibiotics, or alcohols. Non-restrictive examples of tissue-specific promoters include the B29 promoter, CD14 promoter, CD43 promoter, CD45 promoter, CD68 promoter, desmin promoter, elastase-1 promoter, endoglin promoter, fibronectin promoter, Flt-1 promoter, GFAP promoter, GPIIb promoter, ICAM-2 promoter, INF-β promoter, Mb promoter, NphsI promoter, OG-2 promoter, SP-B promoter, SYN1 promoter, and WASP promoter. Promoter sequences can be wild-type or can be modified for more efficient or effective expression.

[0077] In several embodiments, nucleic acids encoding programmable DNA-modifying proteins and / or at least one programmable DNA-binding protein may be present in a vector. Suitable vectors include plasmid vectors, phagemids, granules, artificial / miniature chromosomes, transposons, and viral vectors (e.g., lentiviral vectors, adeno-associated virus vectors, adenovirus vectors, etc.). In one embodiment, DNA encoding programmable DNA-modifying proteins and / or at least one programmable DNA-binding protein may be present in a plasmid vector. Non-limiting examples of suitable plasmid vectors include pUC, pBR322, pET, pBluescript, and variants thereof. In other embodiments, nucleic acids encoding programmable DNA-modifying proteins and / or at least one programmable DNA-binding protein may be present in a viral vector. The plasmid or viral vector may contain additional expression control sequences (e.g., enhancer sequences, Kozak sequences, polyadenylation sequences, transcription termination sequences, etc.), selection marker sequences (e.g., antibiotic resistance genes), origin of replication, etc. Further information can be found in "Current Protocols in Molecular Biology" Ausubel. et al. , John Wiley & Sons, New York, 2003 or "Molecular Cloning: A Laboratory Manual" Sambrook & Russell, Cold Spring Harbor Press, Cold Spring Harbor, NY, 3 rd Found in edition, 2001.

[0078] In embodiments where the programmable DNA-modifying protein and / or at least one programmable DNA-binding protein comprises a CRISPR / Cas protein or a variant thereof, the expression vector comprising a nucleic acid encoding the programmable DNA-modifying protein and / or at least one programmable DNA-binding protein may further comprise a sequence encoding one or more guide RNAs. The sequence encoding the guide RNA is typically operatively linked to at least one transcriptional control sequence for expression of the guide RNA in target eukaryotic cells. For example, the nucleic acid encoding the guide RNA may be operatively linked to a promoter sequence recognized by RNA polymerase III (Pol III). Examples of suitable Pol III promoters include, but are not limited to, mammalian U6, U3, H1, and 7SL RNA promoters.

[0079] (d) Specific Composition In some embodiments, the programmable DNA-modifying protein and one or more programmable DNA-binding proteins are provided as proteins (or, in some cases, as protein-RNA complexes). The programmable DNA-modifying protein and the programmable DNA-binding protein can be expressed in bacterial or eukaryotic cells and purified using methods well known in the art. In other embodiments, the programmable DNA-modifying protein and one or more programmable DNA-binding proteins are provided as encoding nucleic acids.

[0080] In some embodiments, the composition may comprise one programmable DNA-binding protein / system or encoding nucleic acid. In other embodiments, the composition may comprise two programmable DNA-binding proteins / systems or encoding nucleic acids. In other embodiments, the composition may comprise three programmable DNA-binding proteins / systems or encoding nucleic acids. In a further embodiment, the composition may comprise four programmable DNA-binding proteins / systems or encoding nucleic acids. In other embodiments, the composition may comprise five or more programmable DNA-binding proteins / systems or encoding nucleic acids.

[0081] In specific embodiments, the programmable DNA-modifying protein may comprise a CRISPR / Cas system (e.g., a CRISPR / Cas nuclease, a CRISPR / Cas double-nicking enzyme, or a non-catalytically inactive (dead) CRISPR / Cas protein linked to a non-nuclease-modifying domain), and the programmable DNA-binding protein may be a CRISPR / Cas system lacking nuclease activity. For example, the programmable DNA-binding protein may be a non-catalytically inactive CRISPR / Cas system. Typically, each CRISPR / Cas protein contains at least one nuclear localization signal. In some iterations, the composition may comprise a CRISPR / Cas system as a CRISPR / Cas protein and guide RNA, wherein the protein and RNA may be separate entities or the protein and RNA may be complexed together. The guide RNA may be at least partially chemically synthesized. The guide RNA may be enzymatically synthesized. In other iterations, the composition may comprise a CRISPR / Cas protein and DNA encoding the guide RNA. In other iterations, the composition may comprise mRNA encoding the CRISPR / Cas protein and DNA encoding the guide RNA. In other iterations, the composition may comprise a plasmid or viral vector encoding a CRISPR / Cas protein and / or guide RNA. In some embodiments, the catalytically active CRISPR / Cas protein and the catalytically inactivated (dead) CRISPR / Cas protein are Cas9 proteins. The nucleic acids encoding the CRISPR / Cas proteins are typically codon-optimized for optimal expression in target eukaryotic cells.

[0082] Reagent test kit Another aspect of this disclosure provides a kit comprising the compositions detailed above in section (I). As detailed above, the kit may provide a programmable DNA-modifying protein and at least one programmable DNA-binding protein as a protein, a protein-RNA complex, or a nucleic acid encoding various components. The kit may further comprise transfection reagents, cell growth media, selection media, in vitro transcription reagents, nucleic acid purification reagents, protein purification reagents, buffers, etc. The kits provided herein typically include instructions for carrying out the methods detailed below. The instructions included in the kit may be affixed to packaging material or may be included as a package insert. While instructions are typically written or printed materials, they are not limited thereto. This disclosure is contemplated to allow storage of these instructions and delivery to end users on any medium. Such media include, but are not limited to, electronic storage media (e.g., disks, magnetic tapes, cartridges, chips), optical media (e.g., CD-ROMs), etc. As used herein, the term "instructions" may include the address of an Internet site where the instructions are provided.

[0083] In some embodiments, the programmable DNA-modifying protein and / or at least one programmable DNA-binding protein of the kit may comprise a type II CRISPR / Cas system. In some embodiments, the guide RNA of the type II CRISPR / Cas system may comprise crRNA and tracrRNA. Thus, the kit can provide universal tracrRNA(s), and the end user of the kit can provide sequence-specific crRNA(s). In some aspects, the kit may comprise a type II CRISPR / Cas protein and tracrRNA(s). In other aspects, the kit may comprise mRNA or DNA encoding a type II CRISPR / Cas protein and DNA encoding tracrRNA.

[0084] In other embodiments, the programmable DNA-modifying protein and / or at least one programmable DNA-binding protein of the kit may comprise a type V CRISPR / Cas system. As described above, the guide RNA of the type V CRISPR / Cas system comprises only crRNA. In some aspects, the kit may comprise a type V CRISPR / Cas protein and crRNA(s), or the kit may comprise mRNA or DNA encoding a type V CRISPR / Cas protein and DNA encoding crRNA(s). In other aspects, the kit may comprise only a type V CRISPR / Cas protein or nucleic acid encoding a type V CRISPR / Cas protein, wherein the end user of the kit provides the crRNA(s).

[0085] (III) Methods to improve accessibility to targeted chromosomal loci Another aspect of this disclosure includes methods for improving the efficiency and / or specificity of targeted genomic / epigmoid modifications in eukaryotic cells by increasing the accessibility of programmable DNA-modifying proteins to target sequences in their chromosomal DNA. The method comprises introducing (a) a programmable DNA-modifying protein or a nucleic acid encoding a programmable DNA-modifying protein and (a) at least one programmable DNA-binding protein or a nucleic acid encoding at least one programmable DNA-binding protein into a target eukaryotic cell. The programmable DNA-modifying protein is engineered to recognize and bind to a target sequence in the chromosomal DNA at which the DNA-modifying protein may modify the DNA or a related protein. Each of one or more programmable DNA-binding proteins is engineered to recognize and bind to a sequence near the target chromosomal sequence of the DNA-modifying protein. The programmable DNA-modifying protein and the programmable DNA-binding protein are detailed in section (I) above.

[0086] Typically, the sequence near the target chromosome sequence is located within approximately 250 base pairs on either side of the target chromosome sequence (i.e., upstream or downstream). The nearby site can be located on either strand of the double-stranded DNA. In some embodiments, the sequence near the target chromosome sequence can be located at a position less than approximately 250 bp, less than approximately 200 bp, less than approximately 150 bp, less than approximately 100 bp, less than approximately 75 bp, less than approximately 50 bp, less than approximately 25 bp, less than approximately 20 bp, less than approximately 15 bp, less than approximately 10 bp, or less than approximately 5 bp from the target chromosome sequence of the DNA-modified protein. In some embodiments, the sequence near the target chromosome sequence may be located at a position of approximately 1 bp to approximately 10 bp, approximately 11 bp to approximately 20 bp, approximately 21 bp to approximately 30 bp, approximately 31 bp to approximately 40 bp, approximately 41 bp to approximately 50 bp, approximately 51 bp to approximately 60 bp, approximately 61 bp to approximately 70 bp, approximately 71 bp to approximately 80 bp, approximately 81 bp to approximately 90 bp, approximately 91 bp to approximately 100 bp, approximately 101 bp to approximately 150 bp, approximately 151 bp to approximately 200 bp, or approximately 201 bp to approximately 250 bp on either side of the target chromosome sequence. In other embodiments, the sequence near the target chromosome sequence may be located at a position of approximately 5 bp to approximately 75 bp, approximately 10 bp to approximately 50 bp, or approximately 15 bp to approximately 25 bp on either side of the target chromosome sequence.

[0087] In some embodiments, the method includes introducing at least one programmable DNA-binding protein into a cell, the binding sequence of which is located upstream or downstream of a target chromosome sequence. In other embodiments, the method includes introducing at least two programmable DNA-binding proteins into a cell, one with a binding sequence located upstream of the target chromosome sequence and the other with a binding sequence located downstream of the target chromosome sequence. In a further embodiment, the method includes introducing at least three programmable DNA-binding proteins into a cell, the binding sequences of which are located upstream or downstream of the target chromosome sequence. In other embodiments, the method includes introducing four or more programmable DNA-binding proteins into a cell, the binding sequences of which are located upstream or downstream of the target chromosome sequence. In these embodiments, for example, the method may include introducing one, two, three, four, five, six, seven, eight, nine, ten, or more than ten programmable DNA-binding proteins, the binding sequences of which are located within approximately 250 bp on either side (i.e., upstream or downstream) of the target chromosome sequence.

[0088] The binding of each of one or more programmable DNA-binding proteins to sites near the target chromosomal sequence alters the local chromatin conformation, leading to increased accessibility of the programmable DNA-modified protein to the (previously inaccessible) target chromosomal sequence (see [link to relevant documentation]). Figure 1 As a result, the modification efficiency of DNA-modifying proteins is improved (see, for example, Examples 1-3). In other words, the modification efficiency of DNA-modifying proteins is improved when they are introduced into cells in combination with one or more programmable DNA-binding proteins, compared to when they are introduced into cells alone.

[0089] Furthermore, the methods disclosed herein improve the specificity of targeted genome modifications. While programmable DNA-modifying proteins are engineered to recognize and bind target sequences at specific chromosomal loci, the same or nearly identical sequences can be present at other chromosomal locations (leading to off-target effects). However, in embodiments where the binding of a programmable DNA-modifying protein to a target chromosomal sequence largely depends on the binding of one or more programmable DNA-binding proteins to sequences near the target chromosomal sequence, the binding of these one or more programmable DNA-binding proteins to sites within the target chromosomal locus close to the target sequence provides additional specificity for the modification event (see Example 4).

[0090] Therefore, the methods disclosed in this paper can improve the efficiency and / or specificity of targeted genome editing (e.g., gene correction, gene knockout, gene knock-in), targeted epigenetic modification, and targeted transcriptional regulation.

[0091] (a) Introducing cells As described above, the method includes introducing into a cell (a) a programmable DNA-modifying protein or a nucleic acid encoding a programmable DNA-modifying protein and (b) at least one programmable DNA-binding protein or a nucleic acid encoding at least one programmable DNA-binding protein. The programmable DNA-modifying protein is detailed in section (I)(a) above, the programmable DNA-binding protein is detailed in section (I)(b) above, and the nucleic acid encoding the DNA-modifying protein or the programmable DNA-binding protein is described in section (I)(c) above.

[0092] The programmable DNA-modified protein or nucleic acid encoding the programmable DNA-modified protein and at least one programmable DNA-binding protein or nucleic acid encoding at least one programmable DNA-binding protein can be introduced into the target cell by a variety of methods.

[0093] In some implementations, cells can be transfected with suitable molecules (i.e., proteins, DNA, and / or RNA). Suitable transfection methods include nuclear transfection (or electroporation), calcium phosphate-mediated transfection, cationic polymer transfection (e.g., DEAE-dextran or polyethyleneimine), viral transduction, virion transfection, viral particle transfection, liposome transfection, cationic liposome transfection, immunoliposome transfection, non-liposomal lipid transfection, dendritic macromolecule transfection, heat shock transfection, magnetic transfection, lipofection, gene gun delivery, impalefection, sonopoversion, optical transfection, and proprietary reagent-enhanced uptake of nucleic acids. Transfection methods are well known in the art (see, for example, "Current Protocols in Molecular Biology" by Ausubel). et al. (John Wiley & Sons, New York, 2003, or “Molecular Cloning: A Laboratory Manual” Sambrook & Russell, Cold Spring Harbor Press, Cold Spring Harbor, NY, 3rd edition, 2001). In other embodiments, the molecules can be introduced into cells via microinjection. For example, the molecules can be injected into the cytoplasm or nucleus of the target cells. The amount of each molecule introduced into the cells can vary, but those skilled in the art are familiar with methods for determining the appropriate amount.

[0094] Multiple molecules can be introduced into a cell simultaneously or sequentially. For example, a programmable DNA-modifying protein (or its encoded nucleic acid) and at least one programmable DNA-binding protein (or its encoded nucleic acid) can be introduced simultaneously. Alternatively, one can be introduced first, followed by another.

[0095] Typically, cells are maintained under conditions suitable for cell growth and / or maintenance. Suitable cell culture conditions are well known in the art and are described, for example, in Santiago. et al ., Proc. Natl. Acad. Sci. USA, 2008, 105:5809-5814; Moehle et al . Proc. Natl. Acad. Sci. USA, 2007, 104:3055-3060;Urnov et al ., Nature, 2005, 435:646-651; and Lombardo et al Nat. Biotechnol., 2007, 25:1298-1306. Those skilled in the art will understand that methods used for culturing cells are known in the art and can and will vary depending on the cell type. In all cases, conventional optimization methods can be used to determine the optimal technique for a particular cell type.

[0096] (b) Targeted genome modification The binding of one or more programmable DNA-binding proteins to sequences near the target chromosome sequence alters local chromatin conformation, for example, changing nucleosome structure and / or displacing histones. Therefore, programmable DNA-binding proteins can access the target chromosome sequence more effectively than when used alone. This increased accessibility leads to improved efficiency and / or specificity of targeted genome modification. Targeted genome / epigenetic modifications can be mediated by DNA-binding proteins with nuclease or non-nuclease activity.

[0097] In embodiments where the programmable DNA-modified protein has nuclease activity, the DNA-modified protein can introduce double-strand breaks at a target chromosomal sequence. Double-strand breaks in the chromosomal sequence can be repaired via a non-homologous end joining (NHEJ) repair process. Because NHEJ is error-prone, deletion of at least one nucleotide, insertion of at least one nucleotide, substitution of at least one nucleotide, or a combination thereof, can occur during break repair. Therefore, the target chromosomal sequence can be modified or inactivated. For example, deletions, insertions, or substitutions in a reading frame shift of a coding sequence can result in altered or absent protein products (referred to as "knockout"). In some iterations, the method may further include introducing a donor polynucleotide (see below) into the cell, the donor polynucleotide containing a donor sequence flanked by a sequence having fundamental sequence identity with a sequence located on either side of the target chromosomal sequence, such that during double-strand break repair via a homologous directed repair (HDR) process, the donor sequence in the donor polynucleotide can be exchanged with or integrated into the chromosomal sequence at the target chromosomal sequence. Integration of the exogenous sequence is referred to as "knock-in". As detailed above, the methods disclosed in this paper also reduce off-target effects, thereby improving the specificity of targeting genome modifications.

[0098] Therefore, in various iterations, the efficiency and / or specificity of targeted genome modification can be improved by at least about 0.1-fold, at least about 0.5-fold, at least about 1-fold, at least about 2-fold, at least about 2-fold, at least about 5-fold, at least about 10-fold, or at least about 20-fold, at least about 50-fold, at least about 100-fold, or more than about 100-fold, compared to using a programmable DNA-modifying protein with nuclease activity alone. For example, when a programmable DNA-modifying protein with nuclease activity is used alone, there may be no detectable indel or integration events. However, when the programmable DNA-modifying protein with nuclease activity is used in combination with at least one programmable DNA-binding protein, indel and integration events can be detected (e.g., at least about 1% indel / integration, at least about 5% indel / integration, at least about 10% indel / integration, at least about 20% indel / integration, at least about 30% indel / integration, at least about 40% indel / integration, at least about 50% indel / integration, or more than about 50% indel / integration).

[0099] In embodiments where the programmable DNA-modified protein has non-nuclease activity, the DNA-modified protein can modify DNA or related proteins at a target chromosomal sequence or modify the expression of the target chromosomal sequence. For example, when the programmable DNA-modified protein contains epigenetic modification activity, histone acetylation, methylation, phosphorylation, adenylation, and other states can be modified, or DNA methylation, amination, and other states can be modified. For example, in embodiments where the programmable DNA-modified protein contains cytosine deaminase activity, one or more cytosine residues on the target chromosomal sequence can be converted to uracil residues. Alternatively, when the programmable DNA-modified protein contains transcriptional activation or repression activity, transcription at the target chromosomal sequence can be increased or decreased. Compared to using a programmable DNA-modified protein with non-nuclease activity alone, the resulting epigenetic modification or transcriptional regulation can be increased by at least about 0.1-fold, at least about 0.5-fold, at least about 1-fold, at least about 2-fold, at least about 5-fold, at least about 10-fold, or at least about 20-fold, at least about 50-fold, at least about 100-fold, or more than about 100-fold.

[0100] The targeted genome modification / epigenetic modification detailed above can be performed alone or in multiple ways (i.e., it can target two or more chromosome sequences simultaneously).

[0101] (c) Optional donor polynucleotides In embodiments where the programmable DNA-modified protein contains nuclease activity, the method may further include introducing at least one donor polynucleotide into the cell. The donor polynucleotide may be single-stranded or double-stranded, linear or circular, and / or may be RNA or DNA. In some embodiments, the donor polynucleotide may be a vector, such as a plasmid vector.

[0102] The donor polynucleotide comprises at least one donor sequence. In some aspects, the donor sequence of the donor polynucleotide can be a modified form of an endogenous or natural chromosomal sequence. For example, the donor sequence may be substantially identical to a portion of a chromosomal sequence at or near the sequence targeted by the DNA-modifying protein, but it contains at least one nucleotide change. Thus, after integration or exchange with the natural sequence, the sequence at the target chromosomal location contains at least one nucleotide change. For example, the change may be the insertion of one or more nucleotides, the deletion of one or more nucleotides, the substitution of one or more nucleotides, or a combination thereof. As a result of the "genetic correction" integration of the modified sequence, the cell can produce a modified gene product from the target chromosomal sequence.

[0103] In other respects, the donor sequence of the donor polynucleotide can be a foreign sequence. As used herein, a "foreign" sequence means a sequence that is not native to the cell, or whose native location is at a different position in the cell's genome. For example, the foreign sequence may contain a protein-coding sequence that can be operatively linked to a foreign promoter control sequence so that, upon integration into the genome, the cell can express the protein encoded by the integrated sequence. Alternatively, the foreign sequence may be integrated into a chromosomal sequence such that its expression is regulated by an endogenous promoter control sequence. In other iterations, the foreign sequence may be a transcriptional control sequence, other expression control sequences, RNA-coding sequences, etc. As described above, the integration of a foreign sequence into a chromosomal sequence is referred to as "knock-in".

[0104] As will be understood by those skilled in the art, the length of the donor sequence can and will vary. For example, the length of the donor sequence can vary from a few nucleotides to hundreds of nucleotides to hundreds of thousands of nucleotides.

[0105] Typically, the donor sequence in the donor polynucleotide is flanked by upstream and downstream sequences that share fundamental sequence identity with the sequences upstream and downstream of the sequence targeted by the programmable DNA-modifying protein, respectively. Due to this sequence similarity, the upstream and downstream sequences of the donor polynucleotide allow homologous recombination between the donor polynucleotide and the target chromosomal sequence, enabling the donor sequence to integrate into (or exchange with) the chromosomal sequence.

[0106] As used herein, an upstream sequence refers to a nucleic acid sequence that has fundamental sequence identity with a chromosomal sequence upstream of the sequence targeted by a programmable DNA-modified protein. Similarly, a downstream sequence refers to a nucleic acid sequence that has fundamental sequence identity with a chromosomal sequence downstream of the sequence targeted by a programmable DNA-modified protein. As used herein, the phrase "fundamental sequence identity" means a sequence having at least about 75% sequence identity. Therefore, upstream and downstream sequences in a donor polynucleotide may have about 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity with the upstream or downstream sequence of the target sequence. In one exemplary embodiment, the upstream and downstream sequences in the donor polynucleotide may have approximately 95% or 100% sequence identity with the chromosomal sequence upstream or downstream of the sequence targeted by the programmable DNA-modified protein.

[0107] In some embodiments, the upstream sequence has fundamental sequence identity with a chromosomal sequence immediately upstream of the sequence targeted by the programmable DNA-modifying protein. In other embodiments, the upstream sequence has fundamental sequence identity with a chromosomal sequence within about one hundred (100) nucleotides upstream of the target sequence. Thus, for example, the upstream sequence may have fundamental sequence identity with a chromosomal sequence within about 1 to about 20, about 21 to about 40, about 41 to about 60, about 61 to about 80, or about 81 to about 100 nucleotides upstream of the target sequence. In some embodiments, the downstream sequence has fundamental sequence identity with a chromosomal sequence immediately downstream of the sequence targeted by the programmable DNA-modifying protein. In other embodiments, the downstream sequence has fundamental sequence identity with a chromosomal sequence within about one hundred (100) nucleotides downstream of the target sequence. Thus, for example, the downstream sequence may have fundamental sequence identity with a chromosomal sequence within about 1 to about 20, about 21 to about 40, about 41 to about 60, about 61 to about 80, or about 81 to about 100 nucleotides downstream of the target sequence.

[0108] Each upstream or downstream sequence can range in length from about 20 nucleotides to about 5000 nucleotides. In some embodiments, the upstream and downstream sequences may contain about 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2800, 3000, 3200, 3400, 3600, 3800, 4000, 4200, 4400, 4600, 4800, or 5000 nucleotides. In a specific embodiment, the upstream or downstream sequence can range in length from about 50 to about 1500 nucleotides.

[0109] (e) Cell type Various cell types are suitable for the methods disclosed herein. Typically, the cells are eukaryotic cells. For example, the cells may be human mammalian cells, non-human mammalian cells, non-mammalian vertebrate cells, invertebrate cells, insect cells, plant cells, yeast cells, or single-celled eukaryotes. In other embodiments, the cells may also be single-celled embryos, which are non-human mammalian embryos. For example, non-human mammalian embryos include rat, hamster, rodent, rabbit, cat, dog, sheep, pig, cattle, horse, and primate embryos. In other embodiments, the cells may be stem cells, such as embryonic stem cells, ES-like stem cells, fetal stem cells, adult stem cells, etc., wherein the embryonic stem cells and fetal stem cells are non-human mammalian cells. In one embodiment, the stem cells are not human embryonic stem cells. Furthermore, the stem cells may include stem cells prepared using the techniques disclosed in WO2003 / 046141 (in its entirety incorporated herein by reference) or Chung et al. (CellStem Cell, 2008, 2:113-117). The cells may be in vitro or in vivo (i.e., within an organism). In an exemplary embodiment, the cells are mammalian cells. In a specific implementation, the cell is a human cell.

[0110] Non-limiting examples of suitable mammalian cells include human embryonic kidney cells (HEK293, HEK293T); human cervical cancer cells (HELA); human lung cells (W138); human hepatocytes (Hep G2); human U2-OS osteosarcoma cells; human A549 cells; human A-431 cells and human K562 cells; Chinese hamster ovary (CHO) cells; young hamster kidney (BHK) cells; mouse myeloma NS0 cells; mouse embryonic fibroblast 3T3 cells (NIH3T3); mouse B lymphoma A20 cells; mouse melanoma B16 cells; mouse myoblast C2C12 cells; mouse myeloma SP2 / 0 cells; mouse embryonic mesenchymal C3H-10T1 / 2 cells; mouse cancer CT26 cells; and mouse prostate Du. CuP cells; mouse mammary EMT6 cells; mouse hepatocellular carcinoma Hepa1c1c7 cells; mouse myeloma J5582 cells; mouse epithelial MTD-1A cells; mouse cardiac MyEnd cells; mouse kidney RenCa cells; mouse pancreatic RIN-5F cells; mouse melanoma X64 cells; mouse lymphoma YAC-1 cells; rat glioblastoma 9L cells; rat B lymphoma RBL cells; rat neuroblastoma B35 cells; rat hepatocellular carcinoma cells (HTC); buffalo rat liver BRL 3A cells; canine kidney cells (MDCK); canine mammary gland (CMT) cells; rat osteosarcoma D17 cells; rat monocyte / macrophage DH82 cells; monkey kidney SV-40 transformed fibroblasts (COS7) cells; monkey kidney CVI-76 cells; African green monkey kidney (VERO-76) cells. Extensive mammalian cell series tables can be found in the American Center for Type Culture Collections (ATCC, Manassas, VA).

[0111] (IV) Methods for detecting specific genomic loci This document also provides methods for detecting or visualizing specific genomic loci in eukaryotic cells. Because the proximity binding of one or more programmable DNA-binding proteins alters chromatin structure and increases the accessibility of programmable DNA-modified proteins to previously inaccessible chromosomal loci, the methods described above in Section (III) can be modified to enhance the detection of specific genomic loci or targeted chromosomal sequences. The methods include introducing into eukaryotic cells (a) a programmable DNA-binding protein comprising at least one detectable marker domain or a nucleic acid encoding a programmable DNA-binding protein comprising at least one detectable marker domain, and (b) at least one programmable DNA-binding protein or a nucleic acid encoding said at least one programmable DNA-binding protein, wherein the programmable DNA-binding protein comprising at least one detectable marker domain targets a target chromosomal sequence, and each of said one or more programmable DNA-binding proteins targets a site near the target chromosomal sequence. Binding at least one programmable DNA-binding protein to a site near the target chromosomal sequence increases the accessibility of the programmable DNA-binding protein comprising at least one detectable marker domain to the target chromosomal sequence. The methods further include detecting the programmable DNA-binding protein comprising at least one detectable marker domain that binds to the target chromosomal sequence.

[0112] The programmable DNA-binding protein comprising at least one detectable labeling domain includes a programmable DNA-binding domain. Suitable programmable DNA-binding domains are described in sections (I)(a)(vi) above. In specific embodiments, the programmable DNA-binding domain may be a catalytically inactive CRISPR / Cas system, a catalytically inactive broad-spectrum nuclease, a zinc finger protein, or a transcription activator-like effector. The at least one detectable labeling domain of the programmable DNA-binding protein may be a fluorescent protein (e.g., GFP, eGFP, RFP, etc.), a fluorescent tag, or an epitope tag (described in sections (I)(a)(i) above). In some embodiments, the at least one detectable labeling domain of the programmable DNA-binding protein may be a naturally occurring epitope within the programmable DNA-binding protein, allowing the programmable DNA-binding protein to be detected by antibodies against the programmable DNA-binding protein. The programmable DNA-binding protein comprising at least one detectable labeling domain may further include at least one nuclear localization signal and / or cell penetration domain, as described in sections (I)(a)(i) above. In some embodiments, the programmable DNA-binding protein comprising at least one detectable marker domain may further comprise a non-nuclease-modified domain (as described in sections (I)(a)(vi) above).

[0113] The one or more programmable DNA-binding proteins are described in section (I)(b) above. Typically, the at least one programmable DNA-binding protein may be a non-catalytically active CRISPR / Cas protein, a non-catalytically active broad-spectrum nuclease, a zinc finger protein, a transcription activator-like effector, a CRISPR / Cas nickase, a ZFN nickase, a TALEN nickase, or a broad-spectrum nuclease nickase.

[0114] The method further includes detecting a programmable DNA-binding protein containing a detectable labeled domain that binds to a target chromosome sequence. This detection can be performed using dynamic live-cell imaging, fluorescence microscopy, confocal microscopy, immunofluorescence, immunoassay, RNA-protein binding, protein-protein binding, etc. The detection step can be performed in live cells or fixed cells.

[0115] In embodiments where the method includes detecting chromatin structure dynamics in living cells, a programmable DNA-binding protein comprising a detectable labeled domain and one or more programmable DNA-binding proteins may be introduced into the cell as a protein or nucleic acid, substantially as described in section (III)(a) above. In embodiments where the method includes detecting a targeted chromosomal sequence in fixed cells, a programmable DNA-binding protein comprising a detectable labeled domain and a programmable DNA-binding protein may be introduced into the cell as a protein (or an RNA-protein complex). Methods for fixing and permeabilizing cells are well known in the art. In some embodiments, the fixed cells may undergo a chemical and / or thermal denaturation process to convert double-stranded chromosomal DNA into single-stranded DNA. In other embodiments, the fixed cells do not undergo a chemical and / or thermal denaturation process.

[0116] In a specific implementation, the programmable DNA-binding protein containing a detectable labeling domain is a fusion protein containing a non-catalytically active (or dead) CRISPR / Cas protein and a fluorescent protein labeling domain, and the at least one programmable DNA-binding protein is a non-catalytically active (or dead) CRISPR / Cas protein.

[0117] In embodiments where at least one programmable DNA modification or DNA-binding protein comprises a CRISPR / Cas protein, the guide RNA may further comprise a detectable marker (e.g., FISH or CISH) for in situ detection. The detectable marker is detailed in sections (I)(a)(i) above. In some embodiments, the programmable DNA modification and the DNA-binding protein each comprise a CRISPR / Cas protein and each guide RNA comprises at least one detectable marker, thereby increasing the quantity or intensity of the signal to be detected.

[0118] In other embodiments, a proximity-bound programmable DNA-modified protein and one or more programmable DNA-binding proteins can be detected by a proximity-linking assay. For example, the programmable DNA-modified protein can be bound by a first antibody, and at least one programmable DNA-binding protein can be bound by a second antibody, each of which can be directly or indirectly (e.g., via the second antibody) linked to a single-stranded proximity-detection oligonucleotide. In other embodiments, the single-stranded proximity-detection oligonucleotide can be directly or indirectly linked to a guide RNA. In other embodiments, the single-stranded proximity-detection oligonucleotide can be directly or indirectly linked to a programmable DNA-modified protein or a programmable DNA-binding protein. A proximity-detection oligonucleotide complexed with a nearby chromosome-binding protein can be detected by an in situ proximity-dependent amplification reaction. The in situ proximity-dependent amplification reaction can be a proximity-linking assay (PLA, see Söderberg, et al., Nature Methods, 2006, 3(12):995-1000) or a proximity-dependent initiation of a hybridization chain reaction (proxHCR, see Koos et al., Nature Communications, 2015, 6:7294, 10 pp.).

[0119] (V) Application The compositions and methods disclosed herein can be used for a variety of therapeutic, diagnostic, industrial, and research applications. In some embodiments, the disclosure can be used to modify any target chromosomal sequence in cells, animals, or plants to mimic and / or study gene function, study genetic or epigenetic conditions of interest, or study biochemical pathways involved in a variety of diseases or conditions. For example, transgenic organisms mimicking diseases or conditions can be produced, wherein the expression of one or more nucleic acid sequences associated with the disease or condition is altered. These disease models can be used to study the effects of mutations on organisms, study disease development and / or progression, study the effects of pharmaceutically active compounds on diseases, and / or evaluate the efficacy of potential gene therapy strategies.

[0120] In other embodiments, the compositions and methods can be used for efficient and cost-effective functional genomic screening, which can be used to study the function of genes involved in specific biological processes and how any changes in gene expression affect biological processes, or to perform saturation or depth scan mutagenesis of genomic loci in conjunction with cell phenotype. Saturation or depth scan mutagenesis can be used to determine key minimum characteristics and discrete vulnerabilities of functional elements required for, for example, gene expression, drug resistance, and disease reversal.

[0121] In further embodiments, the compositions and methods disclosed herein can be used for diagnostic testing to determine the presence of a disease or condition and / or to determine treatment options. Examples of suitable diagnostic tests include the detection of specific mutations in cancer cells (e.g., specific mutations in EGFR, HER2, etc.), the detection of specific mutations associated with specific diseases (e.g., trinucleotide repeats, β-globin mutations associated with sickle cell disease, specific SNPs, etc.), hepatitis detection, and virus detection (e.g., Zika).

[0122] In other embodiments, the compositions and methods disclosed herein can be used to correct gene mutations associated with specific diseases or conditions, such as correcting globin gene mutations associated with sickle cell disease or thalassemia, correcting adenosine deaminase gene mutations associated with severe combined immunodeficiency (SCID), reducing the expression of the causative gene HTT in Huntington's disease, or correcting rhodopsin gene mutations for the treatment of retinitis pigmentosa. These modifications can be performed in vitro in cells.

[0123] In other embodiments, the compositions and methods disclosed herein can be used to produce crop plants with improved traits or increased resistance to environmental stresses. This disclosure can also be used to produce farm animals or production animals with improved traits. For example, pigs possess many characteristics that make them an attractive biomedical model, particularly in regenerative medicine or xenotransplantation.

[0124] definition Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. The following references provide general definitions for many of the terms used in this invention for those skilled in the art: Singleton et al ., Dictionary of Microbiology and MolecularBiology (2nd ed.1994); The Cambridge Dictionary of Science and Technology(Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). As used herein, unless otherwise stated, the following terms have their assigned meanings.

[0125] When describing elements of this disclosure or preferred embodiments thereof, the articles “a,” “an,” “the,” and “the” mean one or more of that element. The terms “comprising,” “including,” and “having” are intended to be inclusive and mean that other elements besides those listed may be present.

[0126] The term "about" when used with respect to numerical values ​​such as x means x ± 5%.

[0127] As used herein, the term "complementarity" or "complementarity" refers to the binding of base pairs in a double-stranded nucleic acid through specific hydrogen bonds. Base pairings can be standard Watson-Crick base pairings (e.g., 5'-AGT C-3' paired with the complementary sequence 3'-T CA G-5'). Base pairings can also be Hoogsteen or reverse Hoogsteen hydrogen bonds. Complementarity is typically measured relative to the double-stranded region, thus excluding protrusions, for example. The complementarity between the two strands of a double-stranded region can be partial and is expressed as a percentage (e.g., 70%) if only a portion (e.g., 70%) of the bases are complementary. Non-complementary bases are "mismatched." Complementarity can also be complete (i.e., 100%) if all bases in the double-stranded region are complementary.

[0128] As used herein, the term “CRISPR / Cas system” refers to a complex containing CRISPR / Cas proteins (i.e., nucleases, nickases, or catalytic death proteins) and guide RNA.

[0129] As used in this article, the term "endogenous sequence" refers to the natural chromosome sequence of a cell.

[0130] As used in this article, the term "exogenous" refers to a sequence that is not native to the cell, or a chromosomal sequence whose native location in the cell's genome is different from that of the chromosome.

[0131] As used herein, "gene" refers to the DNA region (including exons and introns) that encodes a gene product, as well as all DNA regions that regulate the production of gene products, regardless of whether these regulatory sequences are adjacent to coding and / or transcriptional sequences. Therefore, genes include, but are not necessarily limited to, promoter sequences, terminators, translation regulatory sequences such as ribosome binding sites and internal ribosome entry sites, enhancers, silencers, insulators, boundary elements, origins of replication, matrix attachment sites, and locus control regions.

[0132] The term "heterogeneous" refers to an entity that is not endogenous or native to the target cell. For example, a heterologous protein is a protein derived from or originally derived from a foreign protein, such as a foreign-introduced nucleic acid sequence. In some cases, the heterologous protein is not typically produced by the target cell.

[0133] As used herein, the terms “local chromatin structure” or “local chromatin conformation” refer to nucleosome structure and / or histone protein spacers, and generally do not refer to nucleosome compression into chromatin fibers and heterochromatin.

[0134] The term "cleavage enzyme" refers to an enzyme that cuts one strand of a double-stranded nucleic acid sequence (i.e., cleaves the double-stranded sequence). For example, nucleases with double-strand cleavage activity can be modified by mutation and / or deletion to act as cleavage enzymes and cut only one strand of the double-stranded sequence.

[0135] As used in this article, the term "nuclease" refers to an enzyme that cuts both strands of a double-stranded nucleic acid sequence.

[0136] The terms "nucleic acid" and "polynucleotide" refer to deoxyribonucleotides or ribonucleotide polymers that are linear or cyclic conformations and are single-stranded or double-stranded. For the purposes of this disclosure, these terms should not be construed as limitations on polymer length. The terms may include known analogs of natural nucleotides as well as nucleotides modified in the base, sugar, and / or phosphate moieties (e.g., thiophosphate backbone). Generally, analogs of a particular nucleotide have the same base-pairing specificity; that is, an analog of A will pair with a T base.

[0137] The term "nucleotide" refers to deoxyribonucleotides or ribonucleotides. Nucleotides can be standard nucleotides (i.e., adenosine, guanosine, cytidine, thymidine, and uridine), nucleotide isomers, or nucleotide analogs. Nucleotide analogs are nucleotides having modified purine or pyrimidine bases or modified ribose moieties. Nucleotide analogs can be naturally occurring nucleotides (e.g., inosine, pseudouridine, etc.) or non-naturally occurring nucleotides. Non-limiting examples of modifications to the sugar or base moieties of nucleotides include the addition (or removal) of acetyl, amino, carboxyl, carboxymethyl, hydroxyl, methyl, phosphoryl, and thiol groups, as well as the substitution of carbon and nitrogen atoms of the base with other atoms (e.g., 7-denitropurine). Nucleotide analogs also include dideoxynucleotides, 2'-O-methylnucleotides, locked nucleic acids (LNAs), peptide nucleic acids (PNAs), and morpholino nucleic acids.

[0138] The terms “polypeptide” and “protein” are used interchangeably, referring to polymers of amino acid residues.

[0139] As used in this article, the term "nearby site" refers to a binding site or nucleotide sequence located within approximately 250 base pairs on either side of the target sequence in chromosomal DNA.

[0140] As used herein, the term “programmable DNA-modified protein” refers to a protein that is engineered to bind to a specific target sequence in chromosomal DNA and to modify DNA or DNA-related proteins at or near the target sequence.

[0141] As used herein, the term "programmable DNA-binding protein" refers to a protein engineered to bind to a specific target sequence in chromosomal DNA, but which does not modify DNA or DNA-related proteins at or near the target sequence.

[0142] The terms “target sequence,” “target chromosome sequence,” and “target site” are used interchangeably to refer to a specific sequence in chromosomal DNA that a programmable DNA-modifying protein targets, as well as the site at which a programmable DNA-modifying protein modifies DNA or DNA-related proteins.

[0143] Techniques for determining the identity of nucleic acid and amino acid sequences are known in the art. Typically, such techniques involve determining the nucleotide sequence of a gene's mRNA and / or the amino acid sequence it encodes, and comparing these sequences to a second nucleotide or amino acid sequence. Genomic sequences can also be determined and compared in this manner. Generally, identity refers to the exact nucleotide-to-nucleotide or amino acid-to-amino acid correspondence between two polynucleotide or polypeptide sequences, respectively. Two or more sequences (polynucleotides or amino acids) can be compared by determining their percentage identity. The percentage identity between two sequences, whether nucleic acid or amino acid sequences, is the exact number of matches between the two aligned sequences divided by the length of the shorter sequence and multiplied by 100. The local homology algorithm of Smith and Waterman, Advances in Applied Mathematics 2:482-489 (1981), provides an approximate alignment of nucleic acid sequences. The algorithm can be applied to amino acid sequences using a scoring matrix developed by Dayhoff, Atlas of Protein Sequences and Structure, MO Dayhoff ed., 5 suppl. 3:353-358, National Biomedical Research Foundation, Washington, DC, USA, and normalized by Gribskov, Nucl. Acids Res. 14(6):6745-6763 (1986). An exemplary implementation of this algorithm for determining the percentage identity of sequences is provided by GeneticsComputer Group (Madison, Wis.) in the "BestFit" utility application. Other suitable procedures for calculating the percentage identity or similarity between sequences are generally known in the art; for example, another alignment procedure is BLAST, used with default parameters. For example, BLASTN and BLASTP can be used with the following default parameters: genetic code = standard; filter = none; strands = two; cutoff = 60; expectation = 10; matrix = BLOSUM62; description = 50 sequences; sorting basis = HIGH SCORE; database = non-redundant, GenBank+EMBL+DDBJ+PDB+GenBank CDS translations+Swissprotein+Spupdate+PIR. Detailed information about these procedures can be found on the GenBank website.

[0144] Since various changes can be made to the cells and methods described above without departing from the scope of the invention, everything contained in the above description and the embodiments given below should be interpreted as illustrative rather than restrictive.

[0145] List of implementation plans The following listed embodiments are provided to illustrate certain aspects of the invention and are not intended to limit its scope.

[0146] 1. A composition comprising: (a) a programmable DNA-modified protein or a nucleic acid encoding a programmable DNA-modified protein and (b) at least one programmable DNA-binding protein or a nucleic acid encoding at least one programmable DNA-binding protein.

[0147] 2. The composition of embodiment 1, wherein the programmable DNA-modified protein is an RNA-guided clustered regularly spaced short palindromic repeat (CRISPR) / CRISPR-associated (Cas) nuclease system, a CRISPR / Cas dual-nicking enzyme system, a zinc finger nuclease (ZFN), a transcription activator-like effector nuclease (TALEN), a wide range of nucleases, a fusion protein comprising a programmable DNA-binding domain linked to a nuclease domain, or a fusion protein comprising a programmable DNA-binding domain linked to a non-nuclease domain.

[0148] 3. The composition of embodiment 2, wherein the programmable DNA-binding domain of the fusion protein is a non-catalytically active CRISPR / Cas system, a non-catalytically active wide-range nuclease, a zinc finger protein, or a transcription activator-like effector.

[0149] 4. The composition of embodiment 2 or 3, wherein the non-nuclease domain of the fusion protein has acetyltransferase activity, deacetylase activity, methyltransferase activity, demethylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity, deubiquitination activity, adenylation activity, deadenylation activity, SUMOylation activity, deSUMOylation activity, ribosylation activity, deribosylation activity, myristylation activity, demyristylation activity, citrullination activity, helicase activity, amination activity, deamination activity, alkylation activity, dealkylation activity, oxidation activity, transcriptional activation activity, or transcriptional repression activity.

[0150] 5. The composition of embodiment 4, wherein the non-nuclease domain of the fusion protein has cytosine deaminase activity, histone acetyltransferase activity, transcriptional activation activity, or transcriptional repression activity.

[0151] 6. The composition of any one of embodiments 1 to 5, wherein the at least one programmable DNA-binding protein is a non-catalytically active CRISPR / Cas protein, a non-catalytically active broad-spectrum nuclease, a zinc finger protein, a transcription activator-like effector, a CRISPR / Cas nickase, a ZFN nickase, a TALEN nickase, or a broad-spectrum nuclease nickase.

[0152] 7. The composition of any one of embodiments 1 to 6, wherein the nucleic acid encoding the programmable DNA-modified protein and at least one programmable DNA-binding protein is RNA or DNA, and / or wherein the nucleic acid is part of a plasmid vector or a viral vector.

[0153] 8. The composition of any one of embodiments 1 to 6, wherein the programmable DNA modification protein is a CRISPR / Cas nuclease system, a CRISPR / Cas dual-nicking enzyme system, or a non-catalytically inactive CRISPR / Cas system linked to a non-nuclease domain, and the at least one programmable DNA binding protein is a non-catalytically inactive CRISPR / Cas system, wherein each CRISPR / Cas system comprises a CRISPR / Cas protein and guide RNA.

[0154] 9. The composition of embodiment 8, wherein each CRISPR / Cas nuclease system is a type I CRISPR / Cas system, a type II CRISPR / Cas system, a type III CRISPR / Cas system, or a type V CRISPR / Cas system.

[0155] 10. The composition of embodiment 9, wherein each CRISPR / Cas nuclease system is a type II CRISPR / Cas system or a type V CRISPR / Cas system.

[0156] 11. The composition of any one of embodiments 8 to 10, wherein the nucleic acid encoding each CRISPR / Cas protein is mRNA or DNA.

[0157] 12. The composition of any one of embodiments 8 to 11, wherein the nucleic acid encoding each CRISPR / Cas protein and / or the nucleic acid encoding each guide RNA is part of a plasmid vector or a viral vector.

[0158] 13. The composition of any one of embodiments 8 to 11, wherein the guide RNA of each CRISPR / Cas system is enzymatically synthesized.

[0159] 14. The composition of any one of embodiments 8 to 11, wherein the guide RNA of each CRISPR / Cas system is at least partially chemically synthesized.

[0160] 15. A kit comprising a composition of any one of embodiments 1 to 14.

[0161] 16. A method for improving the efficiency and / or specificity of targeted genome modification in eukaryotic cells, the method comprising introducing into eukaryotic cells: Programmable DNA-modified proteins or nucleic acids encoding programmable DNA-modified proteins; and At least one programmable DNA-binding protein or a nucleic acid encoding at least one programmable DNA-binding protein; The programmable DNA-modifying protein targets the target chromosome sequence, and each of the at least one programmable DNA-binding protein targets a site near the target chromosome sequence. The binding of the at least one programmable DNA-binding protein to a site near the target chromosome sequence improves the accessibility of the programmable DNA-modifying protein to the target chromosome sequence, thereby improving the efficiency and / or specificity of targeted genome modification.

[0162] 17. The method of embodiment 16, wherein the site near the target chromosome sequence is located within approximately 250 base pairs on either side of the target chromosome sequence.

[0163] 18. The method of embodiment 17, wherein the site near the target chromosome sequence is located within approximately 100 base pairs on either side of the target chromosome sequence.

[0164] 19. The method of embodiment 18, wherein the site near the target chromosome sequence is located within approximately 75 base pairs on either side of the target chromosome sequence.

[0165] 20. The method of embodiment 19, wherein the site near the target chromosome sequence is located within approximately 50 base pairs on either side of the target chromosome sequence.

[0166] 21. The method of embodiment 20, wherein the site near the target chromosome sequence is located within approximately 25 base pairs on either side of the target chromosome sequence.

[0167] 22. The method of any one of embodiments 16 to 21, wherein the programmable DNA-modified protein is a CRISPR / Cas nuclease system, a CRISPR / Cas dual-nicking enzyme system, a zinc finger nuclease (ZFN), a transcription activator-like effector nuclease (TALEN), a wide range of nucleases, a fusion protein comprising a programmable DNA-binding domain linked to a nuclease domain, or a fusion protein comprising a programmable DNA-binding domain linked to a non-nuclease domain.

[0168] 23. The method of embodiment 22, wherein the programmable DNA-binding domain of the fusion protein is a non-catalytically active CRISPR / Cas system, a non-catalytically active wide-range nuclease, a zinc finger protein, or a transcription activator-like effector.

[0169] 24. The method of embodiment 22 or 23, wherein the non-nuclease-modified domain of the fusion protein has acetyltransferase activity, deacetylase activity, methyltransferase activity, demethylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity, deubiquitination activity, adenylation activity, deadenylation activity, SUMOylation activity, deSUMOylation activity, ribosylation activity, deribosylation activity, myristylation activity, demyristylation activity, citrullination activity, helicase activity, amination activity, deamination activity, alkylation activity, dealkylation activity, oxidation activity, transcriptional activation activity, or transcriptional repression activity.

[0170] 25. The method of embodiment 24, wherein the non-nuclease domain of the fusion protein has cytosine deaminase activity, histone acetyltransferase activity, transcriptional activation activity, or transcriptional repression activity.

[0171] 26. The method of any one of embodiments 16 to 25, wherein the at least one programmable DNA-binding protein is a non-catalytically active CRISPR / Cas system, a non-catalytically active wide range of nucleases, zinc finger proteins, transcription activator-like effectors, CRISPR / Cas nickases, ZFN nickases, TALEN nickases, or wide range of nuclease nickases.

[0172] 27. The method of any one of embodiments 16 to 26, wherein the programmable DNA modification protein is a CRISPR / Cas nuclease system, a CRISPR / Cas dual-nicking enzyme system, or a non-catalytically inactive CRISPR / Cas system linked to a non-nuclease domain, and the at least one programmable DNA binding protein is a non-catalytically inactive CRISPR / Cas system, wherein each CRISPR / Cas system comprises a CRISPR / Cas protein and guide RNA.

[0173] 28. The method of implementation scheme 27, wherein the guide RNA of each CRISPR / Cas system is at least partially chemically synthesized.

[0174] 29. The method of implementation scheme 27, wherein the guide RNA of each CRISPR / Cas system is enzymatically synthesized.

[0175] 30. The method of any one of embodiments 16 to 29, wherein the eukaryotic cells are in vitro.

[0176] 31. The method of any one of embodiments 16 to 29, wherein the eukaryotic cells are in vivo.

[0177] 32. The method of any one of embodiments 16 to 31, wherein the eukaryotic cell is a mammalian cell.

[0178] 33. The method of implementation scheme 32, wherein the mammalian cell is a human cell.

[0179] 34. The method of implementation scheme 32, wherein the mammalian cell is a non-human cell.

[0180] 35. A method for detecting chromosome sequences in eukaryotic cells, the method comprising: I. Introducing into eukaryotic cells (a) a programmable DNA-binding protein comprising at least one detectable marker domain or a nucleic acid encoding a programmable DNA-binding protein comprising at least one detectable marker domain; and (b) at least one programmable DNA-binding protein or a nucleic acid encoding said at least one programmable DNA-binding protein, wherein the programmable DNA-binding protein comprising at least one detectable marker domain targets a target chromosomal sequence, and each of said at least one programmable DNA-binding protein targets a site near the target chromosomal sequence, and the binding of said at least one programmable DNA-binding protein to a site near the target chromosomal sequence improves the accessibility of the programmable DNA-binding protein comprising at least one detectable marker domain to the target chromosomal sequence; and II. Detection of programmable DNA-binding proteins containing at least one detectable marker domain that bind to target chromosome sequences.

[0181] 36. The method of embodiment 35, wherein the site near the target chromosome sequence is located within approximately 250 base pairs on either side of the target chromosome sequence.

[0182] 37. The method of embodiment 36, wherein the site near the target chromosome sequence is located within approximately 100 base pairs on either side of the target chromosome sequence.

[0183] 38. The method of embodiment 37, wherein the site near the target chromosome sequence is located within approximately 75 base pairs on either side of the target chromosome sequence.

[0184] 39. The method of embodiment 38, wherein the site near the target chromosome sequence is located within approximately 50 base pairs on either side of the target chromosome sequence.

[0185] 40. The method of embodiment 39, wherein the site near the target chromosome sequence is located within approximately 25 base pairs on either side of the target chromosome sequence.

[0186] 41. The method of any one of embodiments 35 to 40, wherein the at least one detectable labeling domain of the programmable DNA-binding protein comprising at least one detectable labeling domain is a fluorescent protein, a fluorescent tag, an epitope tag, or a naturally occurring epitope within the programmable DNA-binding protein.

[0187] 42. The method of any one of embodiments 35 to 41, wherein the programmable DNA-binding protein comprising at least one detectable labeling domain is a non-catalytically inactive CRISPR / Cas system linked to at least one detectable labeling domain, a non-catalytically inactive broad-spectrum nuclease linked to at least one detectable labeling domain, a zinc finger protein linked to at least one detectable labeling domain, or a transcription activator-like effector linked to at least one detectable labeling domain.

[0188] 43. The method of any one of embodiments 35 to 42, wherein the at least one programmable DNA-binding protein is a non-catalytically active CRISPR / Cas system, a non-catalytically active wide range of nucleases, zinc finger proteins, transcription activator-like effectors, CRISPR / Cas nickases, ZFN nickases, TALEN nickases, or wide range of nuclease nickases.

[0189] 44. The method of any one of embodiments 35 to 43, wherein the programmable DNA-binding protein comprising at least one detectable marker domain is a non-catalytically active CRISPR / Cas system linked to at least one detectable marker domain, and the at least one programmable DNA-binding protein is a non-catalytically active CRISPR / Cas system, wherein each CRISPR / Cas system comprises a CRISPR / Cas protein and guide RNA.

[0190] 45. The method of implementation scheme 44, wherein the guide RNA of each CRISPR / Cas system is at least partially chemically synthesized.

[0191] 46. ​​The method of implementation scheme 44, wherein the guide RNA of each CRISPR / Cas system is enzymatically synthesized.

[0192] 47. The method of any one of embodiments 35 to 46, wherein the eukaryotic cell is a mammalian cell.

[0193] 48. The method of implementation scheme 47, wherein the mammalian cell is a human cell.

[0194] 49. The method of implementation scheme 47, wherein the mammalian cell is a non-human cell.

[0195] 50. The method of any one of embodiments 35 to 49, wherein the eukaryotic cells are alive or fixed.

[0196] 51. The method of any one of embodiments 35 to 50, wherein the detection includes dynamic live-cell imaging, fluorescence microscopy, confocal microscopy, immunofluorescence, immunoassay, RNA-protein binding, or protein-protein binding. Example

[0197] The following examples illustrate certain aspects of this disclosure.

[0198] Example 1. Enhanced CRISPR-Cas9 (FnCas9) gene editing of the novel culprit, *Francisella novicida*. FnCas9 is a type IIB CRISPR-Cas9. It has higher intrinsic specificity than the widely used SpCas9, but its robustness in human cells has been found to be lower than that of SpCas9. To determine whether the binding of a programmable DNA-binding protein to a nearby site could enable nucleases to cleave normally inaccessible targets in human cells (i.e., the POR locus), K562 cells were transfected with 5.6 μg of FnCas9 plasmid DNA, 5 μg of catalytically killed SpCas9 (SpdCas9) plasmid DNA, and 3 μg of plasmid DNA for each sgRNA (see [link to study]). Figure 2 Genomic DNA was harvested 3 days post-transfection, and the target region was amplified by PCR using the forward primer 5'-CTCCCCTGCTTCTTGTCGTAT-3' (SEQ ID NO:9) and the reverse primer 5'-ACAGGTCGTGGACACTCACA-3' (SEQ ID NO:10). Targeted insertions / deletions of FnCas9 on the target were determined by Cel-I nuclease digestion and polyacrylamide gel electrophoresis.

[0199] like Figure 2 As shown, FnCas9 cannot cleave the target when transfected alone. However, when transfected in combination with SpdCas9 to aid in disrupting local chromatin conformation, FnCas9 is able to cleave the target at a robust level of 10–11% indel when SpdCas9 is used to bind to one nearby site. When SpdCas9 is used to bind to two nearby sites, FnCas9 activity further increases to 28% indel. These results demonstrate that the method disclosed in this paper enables endonucleases to efficiently cleave previously inaccessible targets and exhibits a synergistic effect between the two sites used to disrupt local chromatin conformation.

[0200] Example 2. Enhancement of Campylobacter jejuni CRISPR-Cas9 (CjCas9) gene editing CjCas9 is a type IIC CRISPR-Cas9. It is the smallest Cas9 characterized to date, with unique ACAYPAM requirements. However, this nuclease has been found to be inactive against most targets in human cells. To determine whether the method disclosed herein can enable CjCas9 protein to bind to inaccessible targets in human cells, K562 cells were transfected with 4.2 μg of flag-tagged catalytically dead CjCas9 (CjdCas9) plasmid DNA, 5 μg of catalytically dead SpCas9 (SpdCas9) plasmid DNA, and 3 μg of plasmid DNA for each sgRNA (see [link to article]). Figure 3A Sixteen hours after transfection, cells were fixed in formaldehyde and subjected to chromatin immunoprecipitation (ChIP) using an anti-flag antibody. Target binding of Flag-CjdCas9 was determined by droplet digital PCR (ddPCR).

[0201] like Figure 3C As shown, Flag-CjdCas9 can bind to previously known accessible targets at the AAVS1 locus, but cannot bind to inaccessible targets at the POR locus when transfected alone. However, when transfected in combination with SpdCas9 to disrupt local chromatin conformation, Flag-CjdCas9 binds to POR targets more efficiently than it binds to AAVS1 targets.

[0202] To examine the effect on target DNA cleavage, K562 cells were transfected with 4.2 μg CjCas9 plasmid DNA, 5 μg SpdCas9 plasmid DNA, and 3 μg plasmid DNA per million cells. Genomic DNA was harvested 3 days post-transfection, and the target region was amplified by PCR using the forward primer 5'-CTCCCCTGCTTCTTGTCGTAT-3' (SEQ ID NO:9) and the reverse primer 5'-ACAGGTCGTGGACACTCACA-3' (SEQ ID NO:10). The cleavage activity of CjCas9 on the POR target was determined by Cel-I nuclease digestion and polyacrylamide gel electrophoresis. Figure 4 As shown, CjCas9 cannot cleave the target without SpdCas9. However, when transfected in combination with SpdCas9, CjCas9 can effectively cleave the target with 34.1-37.9% indel. These results demonstrate that the method disclosed in this paper enables nucleases to effectively bind to and cleave previously inaccessible targets.

[0203] Example 3. Enhanced gene editing of the novel culprit, Francisella novicida, Cpf1 (FnCpf1). FnCpf1 is a type V CRISPR-Cas system. The Cpf1 system differs significantly from the type II CRISPR-Cas9 system. Unlike the Cas9 system, the Cpf1 system uses 5'T-rich PAM and a single RNA guide for targeting without the need for tracrRNA (Zetsche et al., Cell, 2015, 163:1-13). These "newer" CRISPR systems have the potential to simplify gene editing practices, but many Cpf1 systems have been found to be inactive in human cells. To determine whether the methods disclosed herein could enable different "inactive" Cpf1 nucleases to cleave endogenous targets in human cells, K562 cells were transfected with 5 μg of FnCpf1 plasmid DNA, 5 μg of SpdCas9 plasmid DNA, and 3 μg of plasmid DNA per million cells (see [link to article]). Figure 5 Genomic DNA was harvested 3 days after transfection, and the target region was amplified by PCR using the forward primer 5'-CTCCCCTGCTTCTTGTCGTAT-3' (SEQ ID NO:9) and the reverse primer 5'-ACAGGTCGTGGACACTCACA-3' (SEQ ID NO:10). The cleavage activity of FnCpf1 on the POR target was determined by Cel-I nuclease digestion and polyacrylamide gel electrophoresis.

[0204] like Figure 5 As shown, FnCpf1 cannot cleave the target when transfected alone, but it can effectively cleave the target when transfected in combination with SpdCas9. These results indicate that the method disclosed in this paper is applicable to different V-type CRISPR-Cas systems.

[0205] Example 4. Selective editing between identical targets in human HBB and HBD Two identical human targets (HBB and HBD) were used to determine whether the methods disclosed herein could facilitate selective editing between identical sites in different genes. K562 cells were transfected with 4.2 μg CjCas9 plasmid DNA, 5 μg SpdCas9 plasmid DNA, and 3 μg plasmid DNA per million cells (see [link to article]). Figure 6Genomic DNA was harvested 3 days after transfection, and two target regions were amplified by PCR. For HBB, the forward primer was 5'-CGGCTGTCATCACTTAGACCTCA-3' (SEQ ID NO:11) and the reverse primer was 5'-GCAGCCTAAGGGTGGGAAAATAGA-3' (SEQ ID NO:12). For HBD, the forward primer was 5'-AGGGCAAGTTAAGGGAATAGTGGAA-3' (SEQ ID NO:13) and the reverse primer was 5'-CCAAGGGTAGACCACCAGTAATCTG-3' (SEQ ID NO:14). The cleavage activity of CjCas9 on the HBB and HBD targets was determined by Cel-I nuclease digestion and polyacrylamide gel electrophoresis.

[0206] like Figure 6 As shown, CjCas9 cannot cleave either target when transfected alone. However, when transfected in combination with SpdCas9, which targets a site adjacent to HBB, CjCas9 effectively cleaves the HBB target, but still cannot cleave the same HBD target. The two Cel-I nuclease digestion bands in the first two lanes were caused by SNPs present in the K562 cell population. These results demonstrate the unique ability of the disclosed method to enhance gene editing selectivity.

[0207] Example 5. Streptococcus pyogenes ( Preptococcus pyogenes CRISPR-Cas9 (SpCas9) gene editing enhancement SpCas9 is a type IIA CRISPR-Cas9 and has been widely used for genome modification due to its robust activity in eukaryotic cells. However, its activity can vary depending on the target. To determine whether the method disclosed herein could also enhance this nuclease, K562 cells were transfected with 5 μg of SpCas9 plasmid DNA, 5.6 μg of catalytically dead FnCas9 (FndCas9), and 3 μg of plasmid DNA per million cells (see [link to article]). Figure 7 Genomic DNA was harvested 3 days after transfection, and the target region was amplified by PCR using the forward primer 5'-CTCCCCTGCTTCTTGTCGTAT-3' (SEQ ID NO:9) and the reverse primer 5'-ACAGGTCGTGGACACTCACA-3' (SEQ ID NO:10). The SpCas9 cleavage activity on the POR target was determined by Cel-I nuclease digestion and polyacrylamide gel electrophoresis.

[0208] like Figure 7As shown, the cleavage activity of SpCas9 was significantly enhanced when transfected in combination with FndCas9 compared to transfection alone. These results indicate that the method disclosed in this paper can also be applied to robust endonucleases.

[0209] Example 6. Enhancing gene editing using ssDNA oligomer donors K562 cells were transfected with 4.2 μg CjCas9 plasmid DNA, 5 μg SpdCas9 plasmid DNA, 3 μg plasmid DNA of each sgRNA, and 300 pmol 88-nt ssDNA oligomer donor per million cells to target integration of EcoRI restriction sites. Genomic DNA was harvested 3 days post-transfection, and the target region was amplified by PCR using the forward primer 5'-CTCCCCTGCTTCTTGTCGTAT-3' (SEQ ID NO:9) and the reverse primer 5'-ACAGGTCGTGGACACTCACA-3' (SEQ ID NO:10). Target integration of EcoRI restriction sites was determined by digestion with EcoRI restriction enzymes and polyacrylamide gel electrophoresis. Figure 8 As shown, when ssDNA oligomer donors were transfected together with CjCas9 and SpdCas9, the restriction sites were efficiently integrated into the POR locus (28–37%), while no integration was detected when the oligonucleotide donor was transfected alone or in combination with CjCas9 without SpdCas9. These results demonstrate that the method disclosed herein can facilitate efficient gene editing using ssDNA oligomer donors on previously inaccessible targets.

[0210] Example 7. Detection of enhanced sequence-specific genomic DNA in live and fixed cells. The fusion of Cas9 protein with fluorescent proteins enables the detection of chromosome dynamics in living cells (Chen et al., Cell, 2013, 155:1479-91). Therefore, chromatin structure dynamics are thought to influence the ability of the CRISPR / Cas system complex to approach various genomic loci. Thus, it is believed that placement of CRISPR (dCas9) complexes adjacent to those containing dCas9-GFP enhances the detection of chromosome dynamics to a degree similar to that observed for chromatin immunoprecipitation in Example 2. For example, CjdCas9 can fuse with GFP and target regions with chromatin states that prevent detectable CjdCas9-GFP binding. SpdCas9-based systems can then be designed adjacent to the CjdCas9-GFP target to generate a detectable signal. For chromatin regions resistant to SpdCas9-GFP binding and detection, adjacent FndCas9 molecules can be used to enhance detection to a degree similar to that shown in Example 5 for enhanced SpCas9 and FndCas9 proximity targeting and double-strand break activity. Furthermore, given that previous studies have shown that the degree of hybridization required between CRISPR guide RNA and genomic DNA may be lower for binding compared to double-strand cleavage (Wu et al ., Nature Biotechnology, 2014, 32(7): 670-6), the use of adjacent CRISPR binding is thought to improve the signal-to-noise ratio for detecting genomic DNA in cells.

[0211] Similar CRISPR-based detection methods have been applied to fixed cells (Deng et al., Proc. Natl. Acad, Sci. USA, 2015, 112(38):11870-75). Therefore, it is believed that proximity CRISPR targeting will enhance the detection of fixed DNA in a manner similar to that described for live cells. Since the genomic DNA strands in fixed cells are chemically cross-linked, reviewing sequence information via hybridization of nucleic acid probes typically requires pretreatment steps involving heating or chemical treatment to adequately separate the strands. Therefore, proximity CRISPR targeting may make fixed DNA more accessible and reduce the extent (or requirement) of heat or chemical treatment of fixed cells. Eliminating heat or chemical treatment will offer advantages in terms of simplified diagnostic protocols and maintenance of intracellular molecular structures, which better reflect live-cell biology and thus provide a better understanding of diagnostic results.

[0212] Example 8. Enhancing CRISPR-based gene activation and repression in eukaryotic cells The fusion of Cas9 proteins with transcriptional regulatory domains has enabled targeted gene activation and repression (Konermann et al., Nature, 2014; 517(7536):583-8; Gilbert et al., Cell, 2014, 159(3):547-661). Chromatin structure dynamics are thought to influence the ability of CRISPR complexes to approach various genomic loci and induce activation or repression. Therefore, placement of CRISPR (dCas9) complexes adjacent to those with dCas9 fused to transcriptional regulatory domains is thought to enhance targeted gene regulation to a degree similar to that observed in chromatin immunoprecipitation in Example 2. For chromatin regions resistant to binding and modification by the SpdCas9-transcriptional-regulator, adjacent FndCas9 molecules can be used to enhance gene activation or repression to a degree similar to that shown in Example 5 for enhanced targeting and double-strand break activity of SpCas9 and FndCas9.

[0213] Example 9. Enhancing CRISPR-based epigenetic modifications in eukaryotic cells Fusion of the Cas9 protein with epigenetic modification domains has enabled targeted epigenetic chromosomal modifications, such as through histone acetylation of p300 or cytosine deamination by cytosine deaminases (Hilton et al., Nat. Biotechnol; 2015, 33(5):510-7; Komor et al., Nature, 2016, 533(7603):420-4). Chromatin structure dynamics are thought to influence the ability of CRISPR complexes to access various genomic loci. Therefore, placement of CRISPR (dCas9) complexes adjacent to those containing dCas9 fused with epigenetic modifiers should enhance targeted epigenetic modifications of chromosomal DNA, local proteins, or local RNA to a degree similar to that observed in chromatin immunoprecipitation in Example 2. For chromatin regions resistant to binding and modification by the SpdCas9-epi-modifier, neighboring FndCas9 molecules can be used to enhance detection to a degree similar to that shown in Example 5 for enhanced SpCas9 and FndCas9 neighbor targeting and double-strand break activity.

Claims

1. A composition comprising: (a) A programmable DNA-modified protein or a nucleic acid encoding a programmable DNA-modified protein, wherein the programmable DNA-modified protein is an RNA-guided clustered regularly spaced short palindromic repeat (CRISPR) nuclease system; (b) at least one programmable DNA-binding protein or a nucleic acid encoding at least one programmable DNA-binding protein, wherein said at least one programmable DNA-binding protein is a CRISPR system lacking nuclease activity; and (c) Donor polynucleotides containing the donor sequence; Each CRISPR system contains CRISPR proteins and guide RNA; The programmable DNA-modifying protein targets the target chromosomal sequence, and each of at least one programmable DNA-binding protein targets a site within 250 base pairs on either side of the target chromosomal sequence; and The programmable DNA-modifying protein is a type II CRISPR protein or a type V CRISPR protein, and the programmable DNA-binding protein is a type II CRISPR protein.

2. The composition of claim 1, wherein at least one programmable DNA-binding protein targets a site within 100 base pairs on either side of a target chromosome sequence.

3. The composition of claim 2, wherein at least one programmable DNA-binding protein targets a site within 75 base pairs on either side of a target chromosome sequence.

4. The composition of claim 3, wherein at least one programmable DNA-binding protein targets a site within 50 base pairs on either side of a target chromosome sequence.

5. The composition of claim 4, wherein at least one programmable DNA-binding protein targets a site within 25 base pairs on either side of a target chromosome sequence.

6. The composition of any one of claims 1-5, wherein the CRISPR system lacking nuclease activity is a non-catalytically active CRISPR protein.

7. The composition of any one of claims 1 to 5, wherein the nucleic acid encoding each CRISPR protein is mRNA or DNA.

8. The composition of any one of claims 1 to 5, wherein the nucleic acid encoding each CRISPR protein and / or the nucleic acid encoding each guide RNA is part of a plasmid vector or a viral vector.

9. The composition of any one of claims 1 to 5, wherein the guide RNA of each CRISPR system is at least partially chemically synthesized.

10. The composition of any one of claims 1 to 5, wherein the guide RNA of each CRISPR system is enzymatically synthesized.

11. A kit comprising the composition of any one of claims 1 to 10.

12. The composition of any one of claims 1-5 or the kit of claim 11, wherein the programmable DNA-modifying protein and at least one programmable DNA-binding protein are different CRISPR protein types or subtypes from each other.

13. The composition of any one of claims 1-5 or the kit of claim 11, wherein Programmable DNA-modifying proteins are type V CRISPR proteins and at least one programmable DNA-binding protein is a type II CRISPR protein.

14. The composition of any one of claims 1-5 or the kit of claim 11, wherein (i) The programmable DNA-modifying protein is a type IIA CRISPR protein and at least one programmable DNA-binding protein is a type IIB CRISPR protein. (ii) The programmable DNA-modifying protein is a type IIB CRISPR protein and at least one programmable DNA-binding protein is a type IIA CRISPR protein. (iii) The programmable DNA-modifying protein is a type IIC CRISPR protein and at least one programmable DNA-binding protein is a type IIA CRISPR protein, or (iv) The programmable DNA-modifying protein is a type V CRISPR protein and at least one programmable DNA-binding protein is a type IIA CRISPR protein.

15. The composition or kit of claim 13, wherein (i) Type II CRISPR proteins are selected from *Francis microbiota* CRISPR-Cas9 (FnCas9), *Campylobacter jejuni* CRISPR-Cas9 (CjCas9), and *Streptococcus pyogenes* CRISPR-Cas9 (SpCas9); and / or (ii) The V-type CRISPR protein is the new culprit, Francisella Cpf1 (FnCpf1).

16. The composition or kit of claim 13, wherein at least one programmable DNA-binding protein is a Cas9 type II CRISPR protein, wherein the Cas9 protein has one or more mutations in each of the RuvC-like domain and the HNH-like domain.

17. The composition or kit of claim 16, wherein (i) one or more mutations in the RuvC-like domain are D10A, D8A, E762A and / or D986A; and / or (ii) one or more mutations in the HNH-like domain are H840A, H559A, N854A, N856A and / or N863A.

18. The composition of any one of claims 1-5 or the kit of claim 11, wherein the donor sequence is an exogenous sequence.

19. The composition of any one of claims 1-5 or the kit of claim 11, wherein the donor polynucleotide is a carrier.

20. The composition of any one of claims 1-5 or the kit of claim 11, wherein the donor polynucleotide is a linear sequence.

21. The composition of any one of claims 1-5 or the kit of claim 11, for therapeutic purposes.

22. The composition of any one of claims 1-5 or the kit of claim 11, for the treatment of sickle cell disease, thalassemia, severe combined immunodeficiency (SCID), Huntington's disease, or retinitis pigmentosa.

23. An in vitro or ex vivo method for targeting genome modifications in eukaryotic cells, the method comprising introducing into eukaryotic cells: (a) A programmable DNA-modified protein or a nucleic acid encoding a programmable DNA-modified protein, wherein the programmable DNA-modified protein is an RNA-guided clustered regularly spaced short palindromic repeat (CRISPR) nuclease system; (b) at least one programmable DNA-binding protein or a nucleic acid encoding at least one programmable DNA-binding protein, wherein said at least one programmable DNA-binding protein is a CRISPR system lacking nuclease activity; and (c) Donor polynucleotides containing the donor sequence; Each CRISPR system contains CRISPR proteins and guide RNA; The programmable DNA-modified protein targets the target chromosomal sequence, and each of at least one programmable DNA-binding protein targets a site near the target chromosomal sequence; The binding of the at least one programmable DNA-binding protein to sites near the target chromosome sequence improves the accessibility of the programmable DNA-modifying protein to the target chromosome sequence, thereby improving the efficiency and / or specificity of targeted genome modification. The programmable DNA-modifying protein is either a type II CRISPR protein or a type V CRISPR protein, and the programmable DNA-binding protein is a type II CRISPR protein; and The sites near the target chromosome sequence are located within 250 base pairs on either side of the target chromosome sequence. The methods described do not include methods for modifying the genetic identity of human germline cells or applications of human embryos for industrial or commercial purposes.

24. The method of claim 23, wherein the site near the target chromosome sequence is located within 100 base pairs on either side of the target chromosome sequence.

25. The method of claim 24, wherein the site near the target chromosome sequence is located within 75 base pairs on either side of the target chromosome sequence.

26. The method of claim 25, wherein the site near the target chromosome sequence is located within 50 base pairs on either side of the target chromosome sequence.

27. The method of claim 26, wherein the site near the target chromosome sequence is located within 25 base pairs on either side of the target chromosome sequence.

28. The method of any one of claims 23-27, wherein the CRISPR system lacking nuclease activity is a CRISPR protein without catalytic activity.

29. The method of any one of claims 23 to 27, wherein the eukaryotic cells are in vitro.

30. The method of any one of claims 23 to 27, wherein the eukaryotic cell is a mammalian cell.

31. The method of claim 30, wherein the mammalian cell is a human cell.

32. The method of any one of claims 23-27, wherein the programmable DNA-modifying protein and at least one programmable DNA-binding protein are different CRISPR protein types or subtypes from each other.

33. The method of any one of claims 23-27, wherein Programmable DNA-modifying proteins are type V CRISPR proteins and at least one programmable DNA-binding protein is a type II CRISPR protein.

34. The method of any one of claims 23-27, wherein (i) The programmable DNA-modifying protein is a type IIA CRISPR protein and at least one programmable DNA-binding protein is a type IIB CRISPR protein. (ii) The programmable DNA-modifying protein is a type IIB CRISPR protein and at least one programmable DNA-binding protein is a type IIA CRISPR protein. (iii) The programmable DNA-modifying protein is a type IIC CRISPR protein and at least one programmable DNA-binding protein is a type IIA CRISPR protein, or (iv) The programmable DNA-modifying protein is a type V CRISPR protein and at least one programmable DNA-binding protein is a type IIA CRISPR protein.

35. The method of claim 33, wherein (i) Type II CRISPR proteins are selected from *Francis microbiota* CRISPR-Cas9 (FnCas9), *Campylobacter jejuni* CRISPR-Cas9 (CjCas9), and *Streptococcus pyogenes* CRISPR-Cas9 (SpCas9); and / or (ii) The V-type CRISPR protein is the new culprit, Francisella Cpf1 (FnCpf1).

36. The method of claim 33, wherein at least one programmable DNA-binding protein is a Cas9 type II CRISPR protein, wherein the Cas9 protein has one or more mutations in each of the RuvC-like domain and the HNH-like domain.

37. The method of claim 36, wherein (i) one or more mutations in the RuvC-like domain are D10A, D8A, E762A and / or D986A; and / or (ii) one or more mutations in the HNH-like domain are H840A, H559A, N854A, N856A and / or N863A.

38. The method of any one of claims 23-27, wherein the donor sequence is an exogenous sequence.

39. The method of any one of claims 23-27, wherein the donor polynucleotide is a carrier.

40. The method of any one of claims 23-27, wherein the donor polynucleotide is a linear sequence.

Citation Information

Patent Citations

  • Seam for sewed articles.

    US1187075A

  • Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells

    WO2003046141A2

  • Optimized CRISPR-CAS double nickase systems, methods and compositions for sequence manipulation

    CN105492611A

  • Compositions and methods for site-directed DNA nicking and cleaving

    WO2016007604A1